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ABSTRACT
Chronic hypoxia (CH)-induced vasoconstriction has been implicated in the
pathogenesis of pulmonary hypertension (pHTN) in infants with chronic cardiorespiratory
disorders. Although endothelial dysfunction, reduced nitric oxide (NO) bioavailability and
oxidative stress contribute to a variety of cardiovascular disorders, their contribution to
enhanced vasoconstrictor reactivity in neonatal pHTN is poorly understood. We
therefore hypothesized that neonatal CH augments pulmonary vasoconstrictor reactivity
by limiting NO-dependent pulmonary vasodilation and by promoting the generation of
reactive oxygen species (ROS).
Enzymatic sources of ROS in the vasculature include NADPH oxidase isoforms,
xanthine oxidase, and uncoupled endothelial nitric oxide synthase (eNOS). The
mitochondria are also a major source of cellular ROS, but surprisingly little is known
about the role of mitochondrial-derived ROS (mitoROS) in neonatal pHTN. Based on
preliminary studies from our laboratory and evidence that protein kinase Cβ (PKCβ)
mediates mitochondrial dysfunction and oxidative stress in neurodegenerative diseases,
we further hypothesized that neonatal CH enhances pulmonary vasoconstrictor
sensitivity via PKCβ-dependent activation of mitoROS generation.
v

To test these hypotheses, we employed pharmacologic approaches to assess
the role of NO, mitoROS and PKCβ on basal vascular tone and agonist-induced
vasoconstrictor sensitivity in both isolated (in situ) lungs and pressurized pulmonary
arteries (~150 μm) from control and CH (2 weeks at 380 mmHg) neonatal rats. CH
neonates displayed elevated right ventricular (RV) systolic pressure (in vivo) and RV
hypertrophy, indicative of pHTN. CH increased both basal pulmonary arterial tone and
vasoconstrictor reactivity to the thromboxane analog, U-46619. Interestingly, we
observed that endogenous NO limits CH-dependent increases in pulmonary
vasoconstriction. Exposure to CH also enhanced NO-dependent vasodilation to arginine
vasopressin (AVP), pulmonary expression of NOS III (eNOS), and eNOS
phosphorylation at activation residue serine-1177. Additional studies using in situ lungs
revealed an effect of scavenging ROS or inhibition of PKCβ to attenuate CH-dependent
increases in basal tone and agonist-induced pulmonary vasoconstrictor sensitivity.
Selective inhibitors of PKCβ or mitoROS similarly reduced basal tone in arteries from CH
rats, while having no effect in control arteries.
We conclude that, in contrast to our hypothesis, enhanced basal tone and
agonist-induced vasoconstriction following neonatal CH is limited by increased NOdependent pulmonary vasodilation resulting from greater eNOS expression and
phosphorylation at activation residue serine-1177. Furthermore, both PKCβ and
mitoROS contribute to enhanced pulmonary vasoconstrictor sensitivity following CH in
neonates. These signaling mediators represent new potential therapeutic targets in the
treatment of neonatal pHTN.
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CHAPTER 1 – INTRODUCTION

Pulmonary hypertension (pHTN) in newborns results from the failure of the
pulmonary circulation to dilate after birth (4, 6). Elevated pulmonary arterial pressure
during infancy or childhood contributes significantly to death and disability (5, 14, 27).
Current therapies depend on strategies to lower pulmonary arterial pressure, such as
inhaled nitric oxide (NO, a potent vasodilator), but have not been demonstrated to
improve mortality or length/cost of hospital stay (27, 191, 204, 273). Advances in our
understanding of neonatal pHTN are therefore needed to facilitate newer,
mechanistically targeted therapies.
Chronic hypoxia (CH) is a common cause of neonatal pHTN and can negatively
impact the developing pulmonary circulation (120). CH is a term used to describe
chronic reductions in arterial oxygen available to the body (general hypoxia) or to a
specific region (tissue hypoxia). Chronic reductions in arterial oxygen levels
(hypoxemia) can result from complications occurring during prenatal and antenatal
pulmonary development. Reduced fetal oxygen supply resulting from limited maternal
oxygen supply (as can occur during exposure to high altitude) or reduced uterine blood
flow (found in placental insufficiency) can lead to pHTN (120). Exposure to CH can also
occur intrapartum, during labor. Intermittent episodes of interrupted fetal oxygenation
can occur during human labor due to uterine contraction, compression of the umbilical
cord, head compression, placental abruption, or rupture of fetal vessels (231, 267).
Most fetuses tolerate these moments of hypoxia, but some do not and hypoxiaassociated disorders such as persistent pHTN of the newborn can result (120). Postnatal exposure to CH usually occurs in newborn babies suffering from parenchymal lung
disease such as bronchopulmonary dysplasia (27, 30), meconium aspiration pneumonia
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(5, 152), or pulmonary hypoplasia resulting from conditions such as congenital
diaphragmatic hernia (249, 260).
Neonatal pHTN resulting from CH exposure is associated with elevated
pulmonary vascular resistance (PVR) that is attributed to luminal narrowing of the
pulmonary arterial circulation resulting from arterial remodeling and vasoconstriction.
Several studies have evaluated factors that influence the degree of pulmonary arterial
remodeling that occurs in the setting of neonatal pHTN (19, 33, 142). Therapy for
neonates with pHTN aims to reduce and perhaps reverse remodeling of the pulmonary
vasculature to facilitate long-term reductions in PVR. Therapies aimed at selective
pulmonary vasodilation however are important for the acute management of neonates
with pHTN. Enhanced pulmonary vasoconstriction following neonatal CH may result
from impaired endothelium-dependent pulmonary vasodilation (19, 87, 89, 129) and
increased production of or sensitivity to vasoconstrictor agonists (15, 40, 91, 233). The
relative contribution of diminished endothelium-dependent pulmonary vasodilation and
enhanced pulmonary vasoconstriction related to increases in basal tone as well as
augmented reactivity to endogenous vasoconstrictor agonists has not been fully
investigated. The following sections outline the normal development and physiology of
the fetal and neonatal pulmonary vasculature and mechanisms contributing to the
development of CH-induced neonatal pHTN.

Development of the Pulmonary Vasculature In Utero
Structure of Arteries. Fetal development of the pulmonary vasculature begins
near the 5th week of gestation and continues after birth, well into the postnatal period
(212). The pulmonary circulation is characterized by three structural motifs for arteries –
fully muscular, partially muscular, and nonmuscular (263). In the fetal lung, the
muscularization of arteries is dependent on vascular external diameter. Based on
2

microscopic evaluation of the fetal pulmonary vasculature, Hislop and Reid observed, “In
all arteries over 200 μm external diameter the wall is muscular. Below 200 μm partially
muscular arteries appear and increase until, in the diameter range 100-75 μm, they
comprise 68% of the population of arteries. Non-muscular arteries appear between 125
and 100 μm and below 37 μm all arteries have this structure,” (127). This sizedependent breakdown of fully to nonmuscularized arteries is present throughout
gestation and is similar to that observed in the pulmonary circulation of adults (127, 263).
Although arteries of similar size have comparable muscularization patterns (fully,
partially, and nonmuscularized vessels) between the fetal and adult pulmonary
circulation, the fetal pulmonary arterial circulation is more muscular and has a larger
percent wall thickness (127). Percent wall thickness represents the thickness of the
arterial wall as a percentage of the external diameter of the vessel (127). The wall of a
given arterial size is twice as muscular in the fetus compared to the adult (127). In the
fetus, when the artery contains muscle, wall thickness is inversely proportional to vessel
diameter with smaller vessels having the highest percentage wall thickness (127).

Hemodynamic Components of Fetal Pulmonary Circulation. Fetal blood is
oxygenated at the placenta and circulated to the fetus (212). A major characteristic of
the fetal cardiopulmonary circulation is that more than 90% of cardiac output is diverted
away from the lungs to other organs via fetal shunts like the foramen ovale and the
ductus arteriosus (153). Shunting of cardiac output away from the lungs in utero is
accomplished by elevated PVR. In utero, fetal PVR is greater when compared to the
systemic circulation (3, 187). Elevated PVR is uncharacteristic for the post-natal
pulmonary circulation, which is characterized by low pressure and low resistance under
normoxic conditions in otherwise healthy adult individuals. Poiseuille’s equation
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describes elements that impact arterial resistance. Per this equation, we expect that
increases in blood viscosity and decreases in luminal radius of the vessel increase PVR.
Increased blood viscosity occurs when hematocrit, or the ratio of the volume of
red blood cells to the total volume of blood, increases. In utero, circulating red blood cell
concentrations gradually increase during the second trimester (weeks 13 – 28),
increasing hematocrit values from 30 – 40%. From the second trimester to term (week
40) the red cell content of blood continues to increase to bring fetal hematocrit to an
average of around 50% (97). The increase in fetal hematocrit occurring during gestation
similarly increases vascular resistance in the pulmonary and systemic circulations.
Considering that PVR is so much greater than systemic vascular resistance in utero,
gestational increase in hematocrit is unlikely to account for enhanced PVR observed in
the fetus.
Decreases in radius of the vessel may account for increased fetal PVR. In
Poiseuille’s equation resistance is inversely proportional to radius to the fourth power,
meaning that halving the radius would increase resistance by 16-fold. As mentioned
above, arteries in the fetal lung are more muscularized relative to the lungs of adults.
This heightened degree of muscularization narrows the lumen of the vessel and
contributes to enhanced fetal PVR (212). Small vessels in the fetal lungs have the
thickest muscular walls and are believed to contribute to the elevation of PVR in utero
(127, 212). Early studies evaluating pulmonary vascular structure in the antenatal period
demonstrate that these smallest vessels dilate at birth and contribute to an immediate
drop in PVR (127). The impact of pulmonary vasodilation occurring at birth suggests
that mechanisms of vasoconstriction contribute to enhanced PVR in utero.

Mechanisms of Fetal Pulmonary Vasoconstriction.
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Increased PVR in utero is due to several mechanisms such as mechanical compression
of pulmonary vessels by fluid-filled airways in the lungs and vasoconstriction of fetal
pulmonary arteries (102, 104).

Fluid-filled airways. Fluid-filled airways are part of gestational lung development
with fetal lung fluid formed by the oncotic force generated by chloride secretion of the
respiratory epithelium into the lumen of the airway (39, 178). In late gestation fetal
lambs, the volume of lung liquid contained in potential airspaces was greater than the
volume of air (functional residual capacity) in newborn lambs (131), indicating that fetal
lungs are hyperexpanded relative to neonatal lungs. Draining lung liquid increased
pulmonary blood flow, whereas tracheal obstruction limited pulmonary blood flow in
these fetal lambs (131). These observations suggest that overexpansion of the fluidfilled airway adds extraluminal pressure on the pulmonary vasculature (266) and
contributes to increased PVR in the fetus (131).

Hypoxic pulmonary vasoconstriction (HPV). Increase of fetal blood oxygen
tension in chronically instrumented lambs either by exposure of pregnant ewes to
hyperbaric hyperoxia or in utero fetal ventilation with 100% oxygen reduces fetal PVR
and increases pulmonary blood flow (24, 26, 188). The pulmonary vasculature is
sensitive to changes in blood oxygen tension in near-term fetal lambs, but due to the
hypoxic nature of the fetal circulation (57), oxygen-dependent vasodilation is absent
(275) and pulmonary arteries demonstrate HPV (77, 78).
HPV describes a physiologic response whereby contraction of pulmonary VSM
increases due to both airway and blood-borne hypoxia, with airway hypoxia as the more
potent stimulus. Hypoxia exposure has been shown to contract isolated VSM cells from
medium and small diameter pulmonary arteries collected from cats, whereas hypoxia5

dependent contraction of VSM cells from cerebral (systemic) arteries was absent (169).
In addition to the hypoxia sensitivity of isolated VSM cells, HPV can be demonstrated in
isolated, ex vivo, perfused lungs (113, 168). Hypoxic sensitivity of isolated VSM cells
and lungs indicates that HPV is a local response to hypoxia and not mediated by
neurovascular reflexes.
HPV typically occurs in two phases with the rapid, first phase intrinsic to the VSM
and the second slower, sustained phase due to the contribution of an endotheliumderived contractile factor (2, 275). The mechanisms that mediate phase 1 of HPV are
controversial. One hypothesis proposes that hypoxia decreases the open probability of
voltage-gated potassium channels (Kv) present on VSM (282). Hypoxia-dependent
reduction of Kv channel open probability can depolarize the VSM membrane (282) and
activate voltage-dependent calcium channels (VDCC) leading to entry of extracellular
calcium (Ca2+) (179). The resulting increase in intracellular Ca2+ concentration ([Ca2+]i)
leads to Ca2+-dependent pulmonary VSM contraction (1, 2, 179). Hypoxia-dependent
inhibition of Kv channels has been linked to decreased production of mitochondrialderived reactive oxygen species (mitoROS), including superoxide (O2-) anion, as oxygen
becomes rate-limiting for ROS generation by the mitochondrial electron transport chain
(1). Decreases in mitoROS shift the balance of cellular redox state to favor net reduction
which further inhibits the Kv channel (282).
An alternative hypothesis for phase 1 of HPV suggests that hypoxia increases
mitoROS levels which shifts the cellular redox state to being more oxidized (78, 275).
An oxidized cellular state triggers VSM cell contraction through the release of Ca2+ from
intracellular stores such as the sarcoplasmic reticulum (SR) and subsequent storeoperated Ca2+ entry (SOCE) (275). Ca2+ flux across the plasma membrane secondary to
depletion of SR Ca2+ stores is termed SOCE. Several studies have shown that phase 1
of HPV is suppressed by depletion of SR Ca2+ stores with cyclopiazonic acid, lanthanum
6

(La3+, a blocker of SOCE), and psalmotoxin (an inhibitor of the store-operated channel,
acid sensing ion channel 1) (1, 195, 227).
Mechanisms regulating phase 2 of HPV involve release of an endotheliumderived contractile factor. Removal of the endothelium of pulmonary arteries either
eliminates or greatly reduces phase 2 of HPV (2, 275). Vasoconstriction occurring
during phase 2 of HPV relies on endothelin-1 (ET-1)-dependent contractile responses in
VSM and increases in myofilament Ca2+ sensitivity due to signaling involving RhoA and
Rho kinase (ROK) (2, 51, 275).
HPV occurring during gestation contributes to elevated PVR and shunting of
cardiac output from the lungs to other organs (77, 78). Of interest, conditions of hypoxia
in utero maintain vasodilation of the ductus arteriosus and the increase in blood oxygen
tension occurring with birth has a direct effect to constrict and close the ductus (121). In
addition to HPV, other mechanisms of vasoconstriction contribute to enhanced PVR in
the fetal pulmonary circulation.

Myogenic response. Unlike the mature pulmonary circulation in adults, the fetal
pulmonary vasculature appears to regulate flow through a myogenic response (251,
262). Acute increases in pulmonary arterial pressure in vivo accomplished by occlusion
of the ductus arteriosus in fetal lambs fitted with an inflatable vascular occluder
increased PVR in the presence of NOS inhibition (251). The pressure-dependent
increase in pulmonary vasoconstriction suggests myogenic regulation. The myogenic
response represents vasoconstriction observed in certain vascular beds that occurs due
to an increase in intraluminal pressure. The response is intrinsic to the VSM (69) and
although observed in the fetal pulmonary circulation, is better characterized in studies of
arteries in the systemic circulation (65, 69, 70, 256).
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In studies of the myogenic response in the systemic circulation, increased
pressure of an isolated blood vessel elicits VSM depolarization (69). Depolarization
opens VDCCs which increases Ca2+ influx and leads to subsequent VSM cell contraction
(69, 123, 294). Stretch-sensitive, non-selective cation channels such as transient
receptor potential channels (TRPs) (64, 123, 192) and epithelial sodium channels (123)
have been proposed to mediate depolarization in the myogenic response. Intracellular
signaling such as the release of Ca2+ from intracellular stores (69, 123) and activation of
kinases, ROK (44, 186) and PKC (186), also contribute to myogenic tone.
TRP channels are expressed in the pulmonary circulation of the fetus, however
their direct contribution to the fetal pulmonary myogenic response has not been
evaluated (40, 102, 108, 203). ROK signaling contributes to the fetal pulmonary
vascular myogenic response (262). Signaling of both ROK (202, 262) and PKC (56) are
important to pulmonary arterial constriction in the fetus.

Agonist-induced pulmonary vasoconstriction. In the fetal pulmonary circulation,
agonist-dependent pulmonary vasoconstriction contributes to fetal PVR (71, 132, 137).
Vasoconstrictive agonists such as ET-1, platelet activating factor (PAF), and serotonin
(5-HT) have been linked to pulmonary vasoconstriction in utero (71, 132, 137).
Vasoconstrictive agonists such as ET-1, PAF, and 5-HT promote VSM contraction by
binding a g-protein coupled receptor on the VSM membrane (133, 274, 290). When
bound to agonist, the receptor’s g-protein subunit disassociates and breaks into Gα and
Gβγ subunits (17). The subunit Gα activates phospholipase C (PLC) which cleaves
membrane phospholipids into diacylglycerol (DAG) and inositol triphosphate (IP3) (162).
DAG has second-messenger properties associated with activation of some downstream
kinases such as PKC and is important for 5-HT-induced intracellular signaling (110). IP3
can bind the IP3-receptor on the SR which leads to Ca2+ release, increased [Ca2+]i, and
8

VSM contraction (133). Vasoconstrictive agonists can also promote Gα-dependent
activation of Rho A/ROK signaling in VSM (145, 167), a response that can contribute to
enhanced myofilament Ca2+ sensitivity (17, 145).
In late-gestation fetal lambs, treatment of chronically instrumented near-term fetal
lambs with ET-1 infusion increases PVR in a manner sensitive to ETA (ET-1 receptor
linked to VSM contraction) receptor blocker, BQ-123 (136). However in other reports,
administration of ET-1 to either chronically instrumented near-term lambs or isolated,
perfused lungs from late gestation fetal sheep lead to dose-dependent pulmonary
vasodilation (48, 50). These findings suggest that the contribution of ET-1 to regulate
fetal pulmonary vascular tone is controversial.
In contrast to the controversial role of ET-1 in the fetal pulmonary circulation,
selective inhibition of the PAF receptor with WEB-2170, in near term fetal lambs,
facilitated a 68% reduction in fetal PVR, suggesting that PAF contributes to elevated
pulmonary vascular tone in utero (132). PAF is synthesized from membrane
phospholipids by phospholipase A2 (PLA2) (132) in a variety of cell types, such as
platelets, macrophages, endothelial cells, and VSM (29, 134). The levels of PAF and
PAF-receptor (PAF-R) in lung tissue are higher in the fetus than in newborn lambs (133,
134). The relatively hypoxic fetal pulmonary circulation may, in part, account for the
increase in both PAF and PAF-R (29, 134). In response to hypoxia, transiently cultured
pulmonary arterial smooth muscle cells (PASMC) collected from fetal lambs increase
protein expression of both PAF-R and PAF (133, 134). Treatment of transiently cultured
PASMCs with PAF facilitated IP3-dependent increases in intracellular Ca2+ that were
augmented following exposure to hypoxia (133). Taken together, these results suggest
that the hypoxic environment of the fetal pulmonary vasculature may facilitate high PVR
through PAF-dependent pulmonary vasoconstriction.
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5-HT is another vasoconstrictor agonist that may contribute to enhanced PVR in
utero (71, 72). 5-HT infusion causes dose-dependent pulmonary vasoconstriction in vivo
in chronically instrumented late-gestation fetal lambs (71). Interestingly, in near-term
fetal lambs, acute infusion of ketanserin, a selective antagonist of a subtype of 5-HT
receptors, 5-HT2A, decreases basal PVR (71) suggesting that 5-HT contributes to
enhanced PVR in utero. Furthermore, selective serotonin reuptake inhibitors (SSRIs),
drugs that prolong 5-HT signaling, such as sertraline and fluoxetine also increase PVR in
late-gestation fetal sheep (71). SSRI-induced fetal pulmonary vasoconstriction is
important because maternal SSRI use in humans has been associated with enhanced
newborn PVR in the antenatal period (49). SSRI-dependent increases in antenatal PVR
may be due to direct actions on the developing pulmonary circulation considering that
SSRIs can cross the placenta (219). Material fluoxetine and sertraline exposure in mice
leads to premature closure of the ductus arteriosus (130). Fetal closure of the ductus
increases PVR in fetal lambs and facilitates persistent elevations of PVR even after
delivery (6, 181). Taken together, these studies indicate that 5-HT is an important
mediator of enhanced PVR in utero.

In summary, enhanced PVR in the fetus is due to several mechanisms: fluid-filled
lungs, HPV, myogenic tone, and agonist-induced pulmonary vasoconstriction. These
mechanisms are important in maintaining shunting of cardiac output from developing
fetal lungs and are vital to the healthy maturation of the pulmonary circulation. High
PVR and shunting of blood from the lungs in utero is possible due to the role of the
placenta in fetal blood oxygenation. After birth, the newborn infant must rely on its lungs
for blood oxygenation. This requirement is associated with a massive shift in
cardiopulmonary perfusion with cardiac output of the right ventricle no longer shunted
from the lungs, but redistributed to them (126). This shift to allow for increased
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pulmonary blood flow is associated with profound pulmonary vasodilation and is
discussed in following sections.

Adaptation of the Pulmonary Vasculature After Birth
Studies investigating the adaptation that occurs in the pulmonary circulation to
allow a newborn to transition from fetal to antenatal life have indicated roles for both
reduced arterial muscularity and vasodilation.

Branching Pattern and Structure. Following birth, new arteries and alveoli
develop within the acinus (128). Neonatal rats, like humans, undergo the alveolar stage
of lung development after birth (61, 260). In rats, the alveolar wall thins, the surface
areas of alveoli expand by 20-fold, and capillary surface area expands by 35-fold (260).
In the preacinar region, the relative percent wall thickness of arteries gradually
decreases throughout infancy. Hislop and Reid compared percent wall thickness in
pulmonary arteries from a three-day old child to the mean for children aged 10 months to
10 years and noted, “[In the child aged 3 days], while the arteries over 200 μm external
diameter still had a percentage wall thickness in the range of the fetal ages, for those
below 200 μm the adult range has been reached. Thinning of the small vessels had
been immediate, probably due to dilation. Only after 4 months had the larger vessels
lost their fetal wall thickness,” (128). From this study and others, it is clear that initial,
rapid reductions in arterial diameter are due to vasodilation and that long-term
reductions in percent wall thickness are due to changes in cytoskeletal structure and
proliferation (114, 118, 126, 128).

Birth-Related Pulmonary Vasodilation. Pulmonary vasodilation occurring after
birth has a rapid onset. In chronically instrumented fetal lambs, pulmonary arterial
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pressure decreases and pulmonary blood flow increases within minutes of birth (4, 164).
After delivery, the mean pulmonary arterial blood pressure decreases to a value lower
than mean arterial blood pressure in the systemic circulation. Greater systemic blood
pressure leads to pressure-dependent closure of the foramen ovale (102). The ductus
arteriosus begins to close within minutes after birth, but does not fully close for several
weeks. Despite the delay in full closure of the ductus, blood flow through the structure
stops within 15 hours after birth (190). Reductions of PVR and closure of fetal shunts
occurring at birth increase pulmonary blood flow to include total cardiac output in the
human infant (102). This is important because at birth the lungs replace the placenta as
the organ of gas exchange and blood oxygenation (126).

Mechanisms of Endothelium-Dependent Pulmonary Vasodilation. The
anatomy of the blood vessel places the endothelium directly adjacent to the layer of
VSM cells and therefore can rapidly influence the tone of VSM cells (95). The
endothelium is also luminally positioned and in direct contact with the blood and can
therefore detect birth-related increases in shear stress related to increased pulmonary
blood flow (3) and increased oxygen tension (47, 68, 122). Following detection of these
birth-related stimuli, the endothelium releases vasoactive mediators such as prostacyclin
(164, 165) and NO (4, 46, 100) to facilitate pulmonary vasodilation and decreases in
PVR.

Prostacyclin. Endothelial cell prostacyclin production is stimulated by shear
stress, changes in blood oxygen tension, and receptor-dependent agonists (164, 235).
In response to these stimuli, Ca2+-dependent activation of phospholipase A2 (PLA2)
generates arachidonic acid (AA) through cleavage of membrane phospholipids.
Prostacyclin is a product of cyclooxygenase (COX)-dependent metabolism of AA.
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Prostacyclin can leave the endothelial cell and bind to the prostacyclin receptor on VSM
cells, leading to VSM relaxation through a mechanism reliant on stimulation of adenylyl
cyclase and production of cyclic adenosine monophosphate (cAMP) (112). COX
expression and the synthesis of prostacyclin are developmentally regulated (42, 164).
The increase in blood oxygenation that occurs with the onset of ventilation at birth
stimulates prostacyclin synthesis (164). In response to the initiation of ventilation, the
decrease in PVR of chronically instrumented newborn lambs occurs in two phases: 1) A
rapid decline (< 30 seconds) and; 2) A slower, more gradual decline that occurs during
the first 10-20 minutes of ventilation (165). Treatment of these lambs with infusions of
indomethacin, an inhibitor of COX, limits only the gradual second phase of ventilationdependent decrease in PVR (165). Thus, the stimulus of ventilation on prostacyclin
release may contribute to postnatal pulmonary vasodilation.

NO. NO derived from the endothelium (100) leads to vasodilation in the perinatal
pulmonary circulation (4). NO is produced during the conversion of L-arginine to Lcitrulline. The conversion is catalyzed by nitric oxide synthase (NOS) (96, 98). There
are three NOS isoforms that contribute to NO formation in the pulmonary circulation of
the fetus and neonate, NOS I (neuronal NOS or nNOS), NOS II (inducible NOS or
iNOS), and NOS III (endothelial NOS or eNOS).
In whole lung tissue collected from fetal rats, nNOS mRNA and protein
expression are increased throughout gestation and then fall rapidly after birth (196). In
chronically instrumented fetal lambs, selective nNOS inhibition increases PVR without
affecting acetylcholine-induced pulmonary vasodilation (217). Moreover, nNOS protein
expression was identified in pulmonary arteries, both with and without the endothelium,
collected from late gestation fetal sheep, suggesting that nNOS may be expressed in the
VSM or adventitial layer of the pulmonary artery during gestation in sheep (217).
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Experiments investigating the contribution of iNOS to PVR in newborn lambs,
demonstrated that selective iNOS inhibition mitigates the ventilation- and oxygendependent fall in PVR that occurs during early postnatal life (215). However, selective
iNOS inhibition in chronically instrumented late gestation fetal lambs only partially
inhibited shear stress dependent increases in pulmonary vasodilation (216). Data from
these studies is consistent with findings in baboons, where iNOS appears to take on a
larger role to impact PVR only after birth (236).
In whole lung tissue collected from fetal rats, both mRNA and protein expression
of eNOS are detectable in late stage gestation and near term at their highest levels
(196). In a separate study using whole lung tissue from neonatal rats, eNOS mRNA and
protein expression were detected at their highest levels within 24 hours after birth with
increased eNOS mRNA persisting for 16 days post-partum (150). Additionally, as
newborn rats age from one to two weeks eNOS protein expression and NO-dependent
regulation of pulmonary vascular tone are increased (53).
Birth-related stimuli such as increases in blood oxygenation (35, 188) and shear
stress (96) stimulate eNOS dependent pulmonary vasodilation. In near term lambs,
ventilation with 100% O2 increases eNOS mRNA and protein expression more than
ventilation with a gas mixture of N2/O2/CO2 (35). In a study of near-term lambs, raising
fetal arterial oxygen tension by exposing pregnant ewes to 100% oxygen at 3
atmospheres of pressure increased the proportion of the right ventricular output
distributed to fetal lungs from 8 to 59% (188). Increased pulmonary blood flow occurring
at birth would likewise increase shear stress on the endothelium. In isolated pulmonary
arterial endothelial cells transiently cultured from late gestation fetal lambs, exposure to
shear stress in vitro increased eNOS mRNA and protein expression (35, 276, 279). In
chronically instrumented, near term fetal lambs fitted with an inflatable vascular occluder
around the ductus arteriosus, compression of the ductus increased pulmonary blood flow
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by 300% and decreased PVR (57). These responses were significantly blunted when
NOS was inhibited by infusions of nitro-L-arginine (57), an L-arginine analog unavailable
for NO production (185). These findings suggest that eNOS contributes to the normal
fall in elevated PVR occurring at birth.

Neonatal Pulmonary Hypertension
Newborn pHTN commonly results from the failure of the pulmonary circulation to
dilate at birth (6). Elevated PVR impedes blood flow through the pulmonary circulation
by remaining greater than systemic vascular resistance (5, 249). This differential leads
to right-to-left shunting of unoxygenated blood across the ductus arteriosus and foramen
ovale and consequential severe hypoxemia (249). Life-threatening circulatory failure
can also result from pHTN (66, 102, 249). Neonatal pHTN resulting from a failure of
post-natal pulmonary vasodilation affects 1.9 per 1000 live births in the United States
and can complicate the course of up to 10% of all infants admitted to the NICU (246).

Mechanisms of Neonatal Pulmonary Hypertension
There are several elements that mediate increased in PVR observed in the
setting of neonatal pHTN and are diagramed in Figure 1 and discussed below.

Polycythemia. Increased circulating concentration of red blood cells has the
potential to increase the viscosity of blood and therefore vascular resistance in a manner
described by Poiseuille’s equation. Erythropoietin is a hormone that stimulates
production of red blood cells in response to either global or tissue hypoxia. Exposure to
fetal hypoxia increases erythropoietin concentration (231). Erythropoietin does not cross
the placenta and therefore, tissue hypoxia stimulates erythropoietin production in the
fetus (283). The liver is the primary site for fetal erythropoietin synthesis and is
15
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Figure 1. Development of Neonatal Pulmonary Hypertension.
Chronic hypoxia (CH) increases pulmonary vascular resistance via polycythemia,
altered vascular structure, decreased vascular growth, and vasoconstriction, all of
which may contribute to neonatal pHTN.
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considered to be the sensor organ for the erythropoietin response to hypoxia (240).
Infants with fetal exposure to CH associated with maternal preeclampsia had elevated
erythropoietin concentrations in amniotic fluid, cord blood (231), and in serum (232).
However, erythropoietin returned to near normal levels within 8 hours of delivery (232).
Hypoxia-dependent changes in erythropoietin expression may impact red blood
cell concentrations. In animal models of neonatal pHTN involving exposure to CH,
hematocrit values in CH exposed neonates are elevated relative to normoxic controls
(52, 148). In neonatal rats exposed to 2 weeks of CH, mean hematocrit values for CH
exposed rats were approximately 40% whereas mean hematocrit values were 30% in
normoxic controls (52, 148). Exposure of adult rats to CH for the same length of time
leads to hematocrit values of 61% for CH and 46% for normoxic controls (52). Although
hematocrit increases in both newborn and adult rats exposed to CH, the hematocrit of
CH exposed neonatal rats equals hematocrit for normoxic adult rats. Modest increases
in hematocrit are also observed in newborn piglets (89) and calves (79) with CH-induced
pHTN. Due to the small size of the increase in hematocrit, it is unlikely that CHdependent polycythemia alone is sufficient to explain elevations in PVR observed in
neonates with pHTN. In a study involving human infants whether either acute or CH
exposure, polycythemia (venous hematocrit >65%) occurred in some patients, but those
infants did not require ventilator support or oxygen treatment (232) whereas infants with
pHTN do require therapeutic interventions (5, 138, 246).

Altered Vascular Structure. The histology of neonatal pHTN is characterized
by thick walled pulmonary arteries (61, 79) that, if untreated, can persist into adulthood
(60, 61, 214). The fully muscularized thick arterial wall observed in neonates with pHTN
is, in part, due to extension of muscle down the arterial tree into previously partial or
non-muscularized arteries (212). The initial thickening of the medial layer of pulmonary
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arteries is due to smooth muscle cell hypertrophy and increases in extracellular
connective tissue (184). VSM cells in the medial layer of pulmonary arteries from
newborn calves and rats show increased cell proliferation and DNA synthesis (183).
Extension of smooth muscle down the vascular tree is thought to be due to proliferation
of smooth muscle cells as well as differentiation of precursor cells such as pericytes in
the non-muscular region of the artery or intermediate cells (fibroblasts) in the partially
muscular region to mature VSM cells (184).
Increased circulating levels of ET-1 in human infants with pHTN (228) and in
various animal models of neonatal pHTN (20, 143, 144, 247) may promote VSM
proliferation and hypertrophy and facilitate arterial remodeling in neonates with pHTN
(20, 143, 144). ET-1 signaling also promotes activity of other growth factors like plateletderived growth factor (141), transforming growth factor-β (139), and nuclear factor of
activated T cells isoform c3 (99) that may additionally play a role in vascular remodeling
occurring in the setting of neonatal pHTN (21, 25, 33, 117). In a study that compared
neonatal fawn-hooded rats (a genetic rat strain that develops pHTN after exposure to
mild CH) to Sprague-Dawley rats (a genetic strain that requires exposure to more severe
CH to develop pHTN), whole lung ET-1 mRNA expression (preproET-1 mRNA) is
elevated 5 days after birth in fawn-hooded rats with no change observed in SpragueDawley rats (247). This elevation occurs before pHTN develops, suggesting that ET-1
may play a role in the development of neonatal pHTN (247). Consistent with this
possibility, chronic ETA receptor (ET-1 receptor present on VSM and endothelial cells)
blockade prevents and partially reverses arterial remodeling occurring in neonatal rats
with CH-induced pHTN (19).
In addition to the role of ET-1 to promote VSM proliferation to vascular
remodeling observed in the setting of neonatal pHTN, it may also contribute to
reductions in VSM apoptosis. In a study of neonatal rats with pHTN, ET-1 signaling can
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limit apoptosis observed in the arterial wall of lungs from neonates with pHTN (140).
Additionally, pulmonary arterial expression of Bax, a proapoptotic factor was decreased
while that of Bcl-xL, an antiapoptotic factor, was increased in lung sections from
neonatal rats with pHTN (140). These results suggests that, in addition to enhanced
proliferation, ET-1 may inhibit apoptosis and promote vascular wall thickening.

Decreased Vascular Growth. In human infants with congenital heart disease
and subsequent pHTN, the number of peripheral arteries is reduced (184, 213). In
models of neonatal pHTN associated with CH such as bronchopulmonary dysplasia
(BPD), reduced numbers of small arteries and an abnormal distribution of vessels within
the distal lung have been described (60, 61). Neonates who survive neonatal pHTN
seem to have a permanent decrease in the number of pulmonary arteries (61). Neonatal
fawn-hooded rats show reduced vessel density and alveolar simplification when raised
at a high altitude in Denver, CO (60). Housing of neonatal rats in hyperbaric chambers
to bring the animals to barometric pressures occurring at sea-level increases vessel
number and promotes alveolar septation and development (60).
Reduced signaling of vascular endothelial growth factor (VEGF) may contribute
to reduced vascular growth in the setting of neonatal pHTN. VEGF is an important
hormone that promotes development and growth of the pulmonary vasculature and
airways (201, 261). The addition of a VEGF receptor inhibitor leads to a reduction in
artery formation and a failure of alveolar septation in growing rats (61). Human infants
and newborn baboons with BPD have reduced lung levels of VEGF and VEGF receptors
(32, 170). Neonatal rats with pHTN also have reduced VEGF levels (173, 261) and
intratracheal adenovirus-mediated VEGF gene therapy increased survival and promoted
development of the lung vasculature and alveoli in these animals (261).
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Vasoconstriction. In additional to the role of polycythemia, altered vascular
structure, and decreased vascular growth described above, enhanced pulmonary
vasoconstriction contributes to increased PVR in neonates with pHTN (88, 180, 250).
Indeed, enhanced PVR occurring in animal models of neonatal pHTN can be
significantly reduced if not fully alleviated by limiting mechanisms of enhanced
pulmonary vasoconstriction (88, 180). In neonatal piglets exposed to CH, elevated PVR
is sensitive to exogenous vasodilator treatment with papaverine (88). Additionally, acute
inhibition of ROK with fasudil alleviates increased PVR observed in neonates with pHTN
(180). In human neonates with pHTN, small precapillary arteries remain undilated after
birth with VSM cells containing more contractile elements such as actin and myosin
heavy chain isoforms (114, 119). This observation is also true in piglets with CHinduced neonatal pHTN (115). These findings in neonates with pHTN suggests that the
VSM of pulmonary arteries is equipped to facilitate more robust VSM contraction and
potentially enhanced pulmonary arterial vasoconstriction.

Mechanisms of Enhanced Vasoconstriction in Neonatal Pulmonary Hypertension
Both basal tone and enhanced pulmonary vasoconstrictor agonist sensitivity
contribute to enhanced pulmonary vasoconstriction in neonates with pHTN (7, 157, 228,
250). A potential mechanism for enhanced basal tone involves the myogenic response.
After birth, the fetal pulmonary myogenic response and subsequent vascular tone is
limited by mechanisms of pulmonary vasodilation (53, 250) and, over time, the
pulmonary circulation becomes a more passive vascular bed not classically associated
with myogenic regulation (44). In newborn lambs fitted with an inflatable vascular
occluder around the ductus arteriosus, acute compression of the ductus leads to NOdependent pulmonary vasodilation (250). In lambs with pHTN however, occluder
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inflation increases in PVR and limits pulmonary arterial blood flow in a manner
consistent with the myogenic response (250).
Enhanced pulmonary vasoconstriction occurring in neonatal pHTN may also be
attributed to increased activity of pulmonary vasoconstrictor agonists. Indeed, in human
infants with pHTN, circulating levels of vasoconstrictor agonists such as ET-1 and
thromboxane A2 are increased (7, 8, 157, 228). Additionally, young children with
congenital heart disease and pHTN demonstrate an imbalance in the biosynthesis of
thromboxane A2 and prostacyclin (both COX products) with greater urinary excretion of
metabolic products of thromboxane A2 and fewer of prostacyclin (7). The regulation of
COX products appears to be important in the development of neonatal pHTN because
babies born to mothers who report high NSAID (inhibitors of COX) use in pregnancy are
at elevated risk of neonatal pHTN (171).
In animal models of neonatal pHTN, the pulmonary vasoconstrictor agonists 5HT and thromboxane A2 contribute to enhanced PVR (72, 90, 93). Acute inhibition of 5HT signaling alleviates enhanced PVR in lambs with pHTN (72) and administration of an
SSRI further increases PVR in these lambs (72) thereby demonstrating that 5-HT
enhances basal pulmonary vascular tone, a response that enhances PVR and perhaps
contributes to pHTN in neonates. Furthermore, acute inhibition of COX-2 (the enzyme
responsible for thromboxane A2 synthesis from AA) augmented AA-induced pulmonary
vasodilation in isolated pulmonary arterial rings from piglets with CH-induced pHTN (90)
suggesting that thromboxane A2 potentiates pulmonary arterial vasoconstriction in
neonates with pHTN. Taken together, these results suggest that vasoconstrictor
agonists contribute to enhanced vasoconstriction in neonates with pHTN.
There are two potential pathways for enhanced basal tone and pulmonary
vasoconstrictor reactivity. The first involves reduced production of vasodilatory
compounds that allows fetal pulmonary arterial tone to be uncovered and persist into
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antenatal life. The second potential mechanism involves enhanced VSM contractility
that may contribute to an augmented myogenic response or augment the action of a
vasoconstrictor agonist. In the literature, evidence to support the existence of both
possibilities is present and discussed below.

Role of Endothelial Dysfunction. Endothelial production of vasodilatory
factors, prostacyclin and NO is limited in the setting of neonatal pHTN (7, 238). In
human infants with pHTN, urinary excretion of prostacyclin metabolites is decreased (7).
In pulmonary arteries of newborn pigs with CH-induced pHTN, the production of
prostacyclin is attenuated (90, 93). In newborn lambs with pHTN, intratracheal
administration of prostacyclin decreased PVR and increased pulmonary arterial blood
flow (221). Moreover, infusion of milrinone, an inhibitor of phosphodiesterase type 3 (an
enzyme that limits prostacyclin-induced vasodilation), decreased baseline PVR and
potentiated the therapeutic effect of intratracheal prostacyclin (221). These findings
support a role for diminished prostacyclin-dependent pulmonary vasodilation to permit
enhanced vasoconstriction in neonates with pHTN.
Limitations on NO-dependent pulmonary vasodilation may additionally contribute
to diminished pulmonary vasodilation observed in neonates with pHTN. Indeed,
decreased eNOS mRNA and protein expression, reduced production of endothelialderived NO (EDNO), and impaired NO-dependent pulmonary vasodilation have all been
documented in animal models of neonatal pHTN (11, 52, 89, 238). Endogenous
inhibitors of eNOS, such as asymmetric dimethylarginine (ADMA) can reduce EDNO
production (23, 264). In human infants with pHTN, urinary ADMA levels are elevated
relative to healthy control infants (205, 264).
In addition to ADMA-dependent reductions in eNOS-derived NO, other factors
that influence eNOS NO production are also altered in neonatal pHTN. Association of
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eNOS with heat shock protein 90 (HSP-90) is correlated with increased NO production
and decreased superoxide anion (O2-) generation (159, 254). Examination of transiently
cultured pulmonary arterial endothelial cells from lambs with pHTN noted decreased
HSP90-eNOS interaction relative to levels observed in cells from healthy neonates
(254). In addition to lower levels of interaction, decreased eNOS-dependent NO
production and elevated O2- generation was also observed (159, 254). This result
suggests that in neonatal pHTN, eNOS association with HSP90 is decreased and eNOS
switches from generation of NO to O2-, thus limiting NO levels.
To promote VSM relaxation, NO stimulates VSM soluble guanylyl cyclase (sGC)dependent production of cyclic guanine monophosphate (cGMP) which in turn activates
protein kinase G (PKG). PKG causes VSM relaxation in two ways, first by decreasing
[Ca2+]i in the VSM and by decreasing Ca2+-sensitivity of the contractile apparatus (149).
In fetal lambs with pHTN, cGMP content and protein expression of sGC is decreased
(36, 281). Additionally, increased pulmonary levels of H2O2 in lambs with pHTN have
been proposed to attenuate both sGC protein expression and activity in pulmonary
arterial VSM (281). Increased expression PKG was observed in neonatal lambs with
CH-induced pHTN, but activity of PKG was decreased in isolated pulmonary arteries
from these lambs (101). These findings suggest that in addition to reduced NO
production, the downstream signaling mechanisms that promote NO-induced VSM
relaxation are also impaired in neonates with pHTN.
In addition to limitations on factors that promote NO-induced VSM relaxation,
there is evidence for augmented levels of enzymes that limit the activity of NO. In
studies of lambs with pHTN, protein expression PDE5 is increased (37). Activity of
PDE5 in VSM is also increased and acute treatment with PDE5 inhibitors decreased
baseline PVR in lambs with pHTN (116) suggesting that PDE5 may potentiate the
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limitation on what small amount of NO-dependent pulmonary vasodilation is present in
neonates with pHTN.
Decreased production of endogenous NO may also contribute to elevated ET-1
levels observed in neonates with pHTN. NO can limit ET-1 production by inhibition of
preproET-1 transcription (151), possibly by decreasing NF- κB activity, an important
transcription factor for ET-1 production (229). ET-1 also regulates NO levels by
downregulation of the expression of eNOS and thus may further potentiate ET-1mediated pulmonary vasoconstriction (277). These studies suggest that reductions in
NO not only limit pulmonary vasodilation, but also increase the amount of the contractile
factor, ET-1 thereby promoting enhanced vasoconstriction in neonates with pHTN.

Role of Enhanced VSM Contractility. An additional contributor to enhanced
pulmonary vasoconstriction in neonatal pHTN is an increase contractility of VSM,
independent of changes in vasodilator levels. Potential contributors to enhanced VSM
contractility in neonates with pHTN include enhanced Ca2+ signaling and increased
myofilament Ca2+ sensitivity.
In studies of neonatal lambs with pHTN, acute treatment with the VDCC inhibitor
nifedipine limits the pulmonary arterial myogenic response (250) suggesting that
enhanced Ca2+ entry contributes to that response in neonates with pHTN. Nifedipine
administration in isolated lungs from piglets exposed to CH leads to profound reductions
in pulmonary arterial pressure with little effect in lungs from control piglets (125),
suggesting that VDCC are important for elevated pulmonary arterial basal tone.
Moreover, isolated pulmonary arterial rings from piglets exposed to CH demonstrate
robust reactivity to the Ca2+ channel agonist, Bay K 8644, a response that is absent in
rings from control neonates (125). Whole cell, voltage-dependent Ca2+ currents are also
exaggerated in isolated VSM from piglets exposed to CH (125). Taken together, these
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studies support a role for VDCC to mediate enhanced pulmonary arterial tone in
neonates with pHTN.
One potential explanation for the increased role of VDCC in mediating enhanced
VSM contractility can be found in the pathway for HPV. HPV can involve the hypoxiadependent reduction of the open probability of voltage-gated potassium channels (Kv)
present on VSM (282). Reduced Kv channel open probability following exposure to
acute hypoxia can depolarize the VSM membrane (282) and activate VDCC leading to
entry of extracellular Ca2+ (179) and Ca2+-dependent pulmonary VSM contraction (1, 2,
179). Kv channel activity is reduced in neonatal lambs with pHTN in a manner that
depends on O2- signaling (158). Additionally, O2- scavengers restore Kv channel function
in isolated arteries from neonatal piglets with CH-induced pHTN (86). Taken together,
these findings indicate that neonatal animals with pHTN demonstrate reduced Kv
channel activity. This impairment of Kv channels may allow for increased VDCC-induced
VSM contractility in neonates with pHTN.
In addition to VDCCs, Ca2+ influx through other Ca2+ permeable ion channels
contributes to increased Ca2+ signaling in VSM of neonates with pHTN (203, 223).
Enhanced contraction of isolated pulmonary arterial rings from lambs with either pre- or
perinatal CH-induced pHTN, is sensitive to inhibitors of TRP channel family members
(40, 108, 203). Enhanced protein expression of TRPC4 (203) and TRPC6 (223) may
contribute to enhanced SOCE-dependent pulmonary arterial vasoconstriction in neonatal
lambs with pHTN (203, 223).
In addition to altered Ca2+-signaling, increased myofilament Ca2+ sensitization
may contribute to enhanced vasoconstriction observed in neonates with pHTN.
Classically, there are two pathways thought to influence myofilament Ca2+ sensitization.
One pathway involves RhoA/ROK-dependent signaling and the other involves activity of
PKC/CPI17. In animal models of neonatal pHTN, levels of activated RhoA are elevated
25

(105, 180). Increased ROK protein expression and activity is observed in adult and
neonatal animals with pHTN, assessed by MYPT1 phosphorylation, a downstream
phosphorylation target of ROK (101, 145, 180). These results suggest that increased
RhoA/ROK signaling contributes to increased myofilament Ca2+ sensitivity due to ROKdependent MYPT1 phosphorylation. Indeed, ROK contributes to enhanced PVR
observed in neonates with pHTN and therapeutic inhibition of ROK normalizes PVR to
that of control neonates (180, 250). These results demonstrate that ROK contributes to
pHTN in neonates, perhaps through promotion of myofilament Ca2+ sensitization.
A separate pathway that promotes myofilament Ca2+ sensitization in the setting
of pHTN involves PKC-dependent activation of CPI-17 that in turn inhibits activity of
myosin light chain phosphatase (242). In studies of isolated lungs from healthy newborn
piglets, PKC inhibition with chelerythrine limits ET-1-dependent pulmonary
vasoconstrictor activity, but has no effect on baseline pulmonary arterial pressure (31).
Moreover, PKC activation with either 1-oleyl-2-acetyl-sn-glycerol (OAG) or phorbol
12,13-dibutyrate (PDBu) leads to dose-dependent pulmonary vasoconstriction in lungs
from control piglets (31). Lungs from piglets with CH-induced pHTN showed enhanced
baseline pulmonary arterial pressure that was reduced after chelerythrine treatment,
suggesting that CH-dependent increases in PVR, in part, depend on PKC signaling (31).

Role of ROS in Vascular Signaling and Pathology
Considering the role of ROK and PKC in mediating enhanced pulmonary
vasoconstriction occurring in the setting of neonatal pHTN, it is important to consider
how their activity may be stimulated. In models of pHTN in adult animals, both ROK and
PKC activity is stimulated by signaling involving reactive oxygen species (ROS) (145,
242). ROS-dependent activation of ROK and PKC signaling may also be occurring in
neonates with pHTN. In transiently cultured pulmonary arterial endothelial cells from
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neonatal piglets with pHTN, activation of Rac1, an enzymatic subunit of NADPH oxidase
(NOX) important for NOX-derived superoxide O2- production (55), leads to downstream
activation of RhoA/ROK signaling (284).
Several PKC isoforms are activated by oxidant stress (16, 54, 155) and contribute
to VSM contraction by increasing [Ca2+]i (193) and enhancing Ca2+ sensitivity of the
myofilament contractile apparatus (172, 186, 194). Studies from adult rats with pHTN
induced by exposure to intermittent hypoxia, demonstrate augmented agonist-dependent
pulmonary vasoconstrictor reactivity through PKCβ-mediated VSM Ca2+ sensitization
(242). PKC also contributes to enhanced pulmonary vasoconstriction and mediates the
vasoconstrictor activity of ET-1 in the hypertensive neonatal pulmonary circulation of
piglets (31). Taken together, these results suggest that oxidant-dependent activation of
Ca2+ sensitization pathways involving ROK and PKC contribute to enhanced pulmonary
vasoconstriction observed in neonatal pHTN.
Considering the oxidant-dependent stimulation of ROK and PKC dependent Ca2+
sensitization, it is interesting to note that in many animal models of neonatal pHTN,
enhanced pulmonary levels of ROS are documented from various subcellular sources
(9, 111, 144). In newborn rats with pHTN, lung levels of lipid peroxidation products such
as 8-isoprostane are elevated and stimulate enhanced pulmonary vascular ET-1
production (144). In newborn lamb models of neonatal pHTN, O2- levels in pulmonary
vessels are increased (9, 111). In addition to promotion of enhanced VSM contractility
through activation of ROK and PKC signaling, increased lung levels of ROS limit the
bioavailability of NO due to scavenging and can thus potentiate vasoconstriction (43,
142). Intratracheal treatment of pulmonary hypertensive lambs with recombinant human
SOD reduces the high levels of pulmonary ROS observed in these animals, increases
eNOS protein expression, and restores NO-dependent pulmonary arterial vasorelaxation
(82). This result suggests that lung production of ROS may contribute to enhanced PVR
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observed in neonates with pHTN through promotion of enhanced VSM contractility and
reductions in NO-dependent pulmonary vasodilation.

Sources of Cellular ROS
A variety of subcellular sources for ROS may contribute to the enhanced level
observed in the pulmonary vasculature of neonates with pHTN. Those sources include
NOX (43, 92, 111), xanthine oxidase (142), uncoupled eNOS (eNOS-dependent O2production instead of NO) (163), and the mitochondria (9, 234).
The mitochondria are a major source of cellular ROS in VSM, but seldom
investigated in the setting of neonatal pHTN (177). MitoROS have been implicated in
the development of pulmonary arterial hypertension in adult rats (22). Additionally, lung
levels of mitoROS are elevated in neonatal sheep with pHTN (9, 83, 234, 280). Potential
stimuli for mitoROS generation in neonates with pHTN includes stretch of VSM cells
(278), as might occur in pulmonary arteries of neonates with increased luminal
pressures and pHTN (6). Transiently cultured PASMC from lambs with pHTN and
healthy controls demonstrated that cyclic stretching increased mitochondrial complex IIIdependent production of O2- (278). Signaling leading to mitoROS production in the
pulmonary circulation has been attributed to uncoupled eNOS (234, 255), reduced
SOD2 (the SOD isoform present in the mitochondria) levels (9), and PKC (222).
Increased mitoROS levels can lead to diminished NO-dependent pulmonary vasodilation
by uncoupling eNOS (234) and promoting the activity of PDE5 (83).
Mitochondrial dysfunction occurring in a number of disease states such as
ischemia-reperfusion injury (270), atherosclerosis (210), diabetic cardiomyopathy (244),
and multiple sclerosis (252) depends on upstream signaling of PKCβ. PKCβ is an
isoform of PKC activated by [Ca2+]i (268) and cellular redox state (106). Despite the link
between PKCβ and mitoROS indicated in a variety of disease states and cell types, the
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contribution of PKCβ to mitoROS generation in the neonatal pulmonary circulation has
not yet been studied.
It is evident that enhanced vasoconstriction plays an important role in mediating
pHTN in neonates and reduced NO-dependent vasodilation and enhanced VSM
contractility contribute to that enhanced vasoconstriction. However, the relative
contribution of both to augmented pulmonary vasoconstriction is unclear. Therefore, the
series of experiments described in this dissertation were designed to examine the roles
of diminished NO-dependent vasodilation and enhanced VSM contractility as well as the
potential contributory signaling mechanisms occurring in neonatal CH-induced pHTN.
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Rationale and Specific Aims
Neonatal pHTN affects 1-2 of every 1000 live births in the United States with
20% of cases being fatal. Surviving patients face significant morbidity associated with
detriments to neural development and chronic lung disease (5, 246). CH is implicated in
the pathogenesis of pHTN (14, 120) and thought to elevate postnatal PVR by increasing
basal arterial tone and by augmenting reactivity to endogenous vasoconstrictor agonists
(15, 40, 233). Enhanced pulmonary vasoconstriction following neonatal CH may result
from a limitation on the production of endothelium-derived relaxing factors or increases
in VSM contractility (19, 87, 89, 114, 119, 129). To investigate the relative contribution
of each, we first investigated mechanisms of reduced endothelium-dependent pulmonary
vasodilation and the contribution of those mechanisms to enhanced vasoconstriction
occurring in neonatal rats with pHTN. ROS mediate reduced NO-dependent
vasodilation in neonates with pHTN (43, 234) and promote VSM contraction by
increasing [Ca2+]i (51) and enhancing myofilament Ca2+ sensitivity (51, 145, 156).
Therefore, we next sought to evaluate the role of ROS in enhanced pulmonary
vasoconstriction occurring in neonates with CH-induced pHTN. Finally, PKCβ
contributes to augmented pulmonary arterial vasoconstriction in adult rodents with pHTN
(242) and leads to mitoROS production in a variety of disorders (210, 244, 252, 270).
Understanding that mitoROS contribute to neonatal pHTN (9, 10, 83), we set out to
investigate the role of PKCβ in stimulating mitoROS production in neonatal PASMC and
the contribution of this signaling pathway to enhanced pulmonary vasoconstriction in
neonates with CH-induced pHTN.
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Specific Aim 1: Determine the contribution of endothelial dysfunction to enhanced
basal tone and agonist-induced vasoconstriction in neonatal pHTN.

Hypothesis: Neonatal CH increases basal tone and pulmonary vasoconstrictor sensitivity
by attenuating NO-dependent pulmonary vasodilation.
1. Assess effects of neonatal CH on regulation of basal tone and agonist-induced
vasoconstriction by endogenous NO.
2. Evaluate the effect of CH on NO-dependent pulmonary vasodilation in neonatal
rats.
3. Assess the effect of neonatal CH on expression of pulmonary NOS.

Approach
To test our hypothesis, we used an isolated (in situ) perfused lung preparation to
evaluate the contribution of endogenous NO to basal and agonist-induced pulmonary
vasoconstriction in normoxic and CH neonatal (2 week old) rats. Additional experiments
examined vasodilatory responsiveness to the receptor-mediated, NO-dependent
pulmonary vasodilator arginine vasopressin (AVP), and assessed pulmonary eNOS
expression and phosphorylation status by western blotting. Our findings demonstrate a
novel effect of neonatal CH to augment NO-dependent vasodilation and to increase
pulmonary eNOS expression and phosphorylation at activation residue Ser-1177,
responses that lessen enhanced basal tone and vasoconstrictor sensitivity to the
thromboxane analog U-46619.
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Specific Aim 2: Establish the contribution of ROS to enhanced vasoconstriction in
CH-induced neonatal pHTN.

Hypothesis: MitoROS contribute to enhanced pulmonary arterial vasoconstriction in
neonates with CH-induced pHTN.
1. Determine the contribution of ROS to enhanced basal tone and vasoconstrictor
reactivity following CH in isolated (in situ) lungs.
2. Evaluate the role of mitoROS in enhanced pulmonary arterial vasoconstriction
following CH in isolated pulmonary arteries.

Approach
To evaluate the hypothesis, we used scavengers of cytosolic ROS in an isolated
(in situ) lung preparation to investigate the role of pulmonary ROS to mediate enhanced
basal tone and agonist-induced vasoconstriction observed in neonates exposed to CH.
In addition to in situ lung experiments, this study included protocols featuring isolated,
pressurized small pulmonary arteries (100-200 μm) from control and CH neonates to
evaluate the contribution of mitoROS to arterial tone. We observed that ROS contribute
to enhanced basal tone and agonist-induced vasoconstriction in lungs from neonatal rats
with pHTN. We additionally found that mitoROS contribute to enhanced tone in isolated
pulmonary arteries from CH-exposed neonates. Our findings demonstrate that mitoROS
contribute to enhanced pulmonary arterial tone in neonates with CH-induced pHTN.
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Specific Aim 3: Define the contribution of PKCβ-signaling to enhanced vascular
reactivity following CH exposure in neonates.

Hypothesis: PKCβ-dependent mitoROS generation in pulmonary vascular smooth
muscle contributes to enhanced pulmonary arterial tone following neonatal CH.
1. Determine the contribution of PKCβ to CH-dependent increases in
vasoconstriction in both isolated (in situ) lungs and isolated pulmonary arteries.
2. Determine the effect of PKCβ stimulation on mitoROS generation in neonatal
pulmonary VSM.
3. Assess the effect of neonatal CH on PKCβ expression.

Approach
To address our hypothesis, we used both isolated (in situ) lungs and pulmonary
arteries to study the contribution of PKCβ to enhanced pulmonary vasoconstriction
observed in neonates following CH exposure. Additional studies examined PKCβdependent mitoROS generation in transiently cultured PASMCs from control neonates
and assessed PKCβ protein expression using western blotting. Our findings suggest that
neonatal CH leads to PKCβ–dependent increases in pulmonary arterial tone and
increased agonist-induced vasoconstriction without increasing PKCβ protein expression.
Additionally, PKCβ promotes mitoROS production in pulmonary VSM of neonatal rats, a
response that may contribute to PKCβ-dependent enhancement of pulmonary
vasoconstriction following CH exposure.

33

CHAPTER 2 – METHODS
General Methods
All protocols used in this study were reviewed and approved by the Institutional
Animal Care and Use Committee of the University of New Mexico Health Sciences
Center.

Experimental Groups and Hypoxic Exposure Protocol
Timed-pregnant Sprague-Dawley (Harlan Industries) rats were allowed to
acclimate for 1 wk before giving birth at ambient normobaric pressure (~630 mmHg in
Albuquerque, NM). Litters selected for exposure to CH were housed in a hypobaric
hypoxic chamber with barometric pressure maintained at 380 ± 5 mmHg for 12 days
[beginning on postnatal day 2 of life]. Age-matched normoxic controls were housed in
similar sham conditions at ambient barometric pressure. Neonates were housed with
their birthing dam. The chamber was opened two times per wk to provide animals with
food, water, and clean bedding. Animals were housed on a 12:12 hour light-dark cycle.

Assessment of Right Ventricular Systolic Pressure (RVSP), Right Ventricular
Weight, and Hematocrit
RVSP and RV hypertrophy were evaluated as indices of pHTN (33, 248). Rats
from each group were anesthetized with ketamine (40 mg/kg) and xylazine (6 mg/kg)
(180). An upper transverse laparotomy was performed, and RVSP was assessed using
a closed-chest transdiaphragmatic approach with a 25-gauge needle attached to a
pressure transducer (Hugo Sachs Electronik-Harvard Apparatus). Entry into the right
ventricle (RV) was confirmed by monitoring the pressure waveform. RVSP and heart
rate were obtained using AT-CODAS data-acquisition software (Dataq Instruments).
Fulton’s index, expressed as the percent ratio of RV to left ventricle and interventricular
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septum (LV+S) weight was used to assess the degree of CH-induced RV hypertrophy.
The polycythemic response to CH was determined by measuring hematocrit (Hct) from
blood samples taken by direct cardiac puncture at the time of lung isolation.

Isolated (in situ) Perfused Rat Lung Preparation
To evaluate the effect of neonatal CH on baseline as well as agonist-dependent
changes in PVR, neonatal rats were anesthetized with pentobarbital sodium (200 mg/kg,
i.p.). The animal was placed on a heating block, the trachea was cannulated and lungs
were ventilated with a positive-pressure mouse ventilator (Hugo Sachs ElectronikHarvard Apparatus) at a tidal volume of 5 ml/kg body wt. and a rate of 100 breaths/min
with a warmed and humidified gas mixture (21% O2/6% CO2/balance N2). Endexpiratory pressure was maintained at 3 cm H2O. After removal of the frontal ribcage,
heparin (5 U, 50 μl) was injected into the RV and the pulmonary artery was cannulated
with custom fitted PE-90 tubing (Becton-Dickinson). The preparation was immediately
perfused with a peristaltic pump (Ismatec) at a rate of 0.1 ml/min with a physiological
saline solution (PSS) containing in mM: 129.8 NaCl, 5.4 KCl, 0.83 MgSO4, 19 NaHCO3,
1.8 CaCl2, and 5.5 glucose with 4% (wt/vol) bovine serum albumin (BSA) (all from
Sigma). Following cannulation of the pulmonary artery, the left ventricle was cannulated
with custom fitted PE-160 tubing. Perfusion rate (Q) was gradually increased to a
maximum of 15 ml/minꞏkg body wt. Perfusion was non-recirculating until the perfusate
exiting the lung was nearly free of blood. Recirculation was then initiated and
maintained for the duration of the experiment. Total recirculating volume was ~3.5 ml.
Following a 20 min equilibration period, an effluent sample of PSS was collected for
determination of pH, Pco2, and Po2 using a handheld iSTAT 1 blood gas analyzer
(Abbott) and iSTAT test cartridges (G3+, Abbott). Lungs were kept in zone 3 conditions
by maintaining venous pressure at 3 mmHg and airway pressure at 1 mmHg (53).
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Pulmonary arterial (Pa) and venous (Pv) pressures were recorded continuously.
Pressures were measured using a P-75 pressure transducer (Hugo Sachs ElectronikHarvard Apparatus) connected to the pulmonary arterial and venous lines. Data were
recorded and processed using data acquisition software and hardware (AT-CODAS,
Dataq Instruments). Total PVR was calculated as (Pa-Pv)/Q.

Assessment of Segmental Vascular Resistance in Isolated (in situ) Rat Lungs
Effects of neonatal CH on basal and agonist-induced changes in arterial and
venous resistance were determined using a double occlusion method as previously
reported (80, 226). Briefly, lungs were isolated as described above and inflow and
outflow lines were simultaneously occluded, allowing arterial and venous pressures to
rapidly equilibrate to an approximation of microvascular capillary pressure (Pc).
Pulmonary arterial resistance was calculated using the formula, (Pa-Pc)/Q, and
pulmonary venous resistance was calculated using, (Pc-Pv)/Q.

Western Blot in Whole Lung Homogenates and Isolated Pulmonary Arteries
Western blots were performed as previously reported (52). Whole lungs
collected from neonates on post-natal day 14 (P14) were snap-frozen in liquid nitrogen
and stored at -80°C. On the day of experimentation, frozen lungs were fragmented with
a mortar and pestle pre-cooled in liquid nitrogen.
In experiments requiring investigation of arterial protein content, pulmonary
arteries were collected from lungs of P14 neonatal pups and snap frozen in liquid
nitrogen and stored at -80°C until assayed.
Frozen lung tissue or pulmonary arteries were added to a Dounce homogenizer
containing ice-cold homogenization buffer [10 mM TrisꞏHCl (pH 7.4), 255 mM sucrose, 2
mM EDTA, 12 μM leupeptin, 4 μM pepstatin A, 1 μM aprotinin, 1% v/v phosphatase
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inhibitor cocktail 3 (cantharidin, (-)-p-bromolevamisole oxalate, and calyculin A) from
Sigma]. Tissue homogenates were sonicated on ice with an ultrasonic homogenizer
(Cole Parmer). Homogenates were then spun at 1500 x g for 10 min in a desktop
centrifuge (Beckman) at 4°C. Sample protein concentrations were assessed using a
NanoDrop (Thermo Fisher Scientific). Samples (15-45 μg/lane) were resolved by SDSPAGE using 7.5% acrylamide gels along with molecular-weight standards (Bio-Rad).
The separated proteins were transferred to polyvinylidene difluoride membranes (BioRad) and blocked for 1 hour at room temperature with 5% nonfat milk (Carnation) and
0.05% Tween-20 (Bio-Rad) in a Tris-buffered saline solution (TBS) containing 10 mM
TrisꞏHCl and 50 mM NaCl (pH 7.5). Blots were then incubated overnight at 4°C with
slight agitation in primary antibody. For each protein of interest, various primary
antibodies were used and are indicated in specific methods for each aim of this study.
Blots were then probed with a horseradish peroxidase-conjugated goat
secondary antibody raised against the animal of origin for the primary antibody (1:3000;
Bio-Rad) in TTBS plus 5% nonfat milk to achieve immunochemical labeling.
Chemiluminescence labeling was performed according to manufacturer instructions
(ECL substrate, Thermo Scientific). Protein bands were detected using
chemiluminescent-sensitive film and band intensity was quantified by densitometric
analysis using ImageJ (NIH). To control for protein loading, all membranes were treated
with Coomassie Brilliant Blue (Bio-Rad) to stain total protein. All bands were normalized
to total protein content in the membrane as assessed by coomassie staining (208).

Calculations and Statistics
Data are expressed as mean ± standard error of the mean (SEM). Values of “n”
indicate numbers of animals per experimental group. A t-test, one-way analysis of
variance (ANOVA), or two-way ANOVA was used to make comparisons between groups
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when appropriate. If differences were detected using ANOVA, individual groups were
further evaluated using a Student-Newman-Keuls post-hoc comparison. Percentage
data were arcsine transformed before statistical comparison. P values of <0.05 were
considered significant.

Protocols for Specific Aims
Protocols for Specific Aim 1
Determine the contribution of endothelial dysfunction to enhanced basal tone and
agonist-induced vasoconstriction in neonatal pHTN.

Protocol Series 1.1: Assess effects of neonatal CH on regulation of basal tone and
agonist-induced vasoconstriction by endogenous NO.
To assess the role of endogenous NO to baseline PVR, lungs from each group
were perfused with PSS containing either saline vehicle or the NOS inhibitor, Nω-nitro-Larginine (L-NNA; 300 μM). We have previously demonstrated that this dose of L-NNA
effectively inhibits NO-dependent pulmonary vasodilation in isolated, perfused lungs
from adult rats (230). After a 20 min equilibration period, Pc was assessed by double
occlusion technique. The contribution of active tone to baseline PVR was assessed by
administration of the NO donor, 1,3-propanediamine, N-{4-[1-(3-aminopropyl)-2-hydroxy2-nitro-sohydrazino]butyl} (spermine NONOate; 100 μM) to maximally dilate the
pulmonary vasculature. A second double occlusion was performed after stabilization of
the response to spermine NONOate. Basal tone is expressed as the change in
resistance to spermine NONOate.
The effect of endogenous NO to limit vasoconstrictor reactivity was determined
by performing cumulative concentration-response curves to the thromboxane analog
9,11-dideoxy-9α,11α-methanoepoxy prostaglangin F2α (U-46619) in the presence and
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absence of L-NNA. Double occlusions were performed to assess Pc under baseline
conditions and following development of a stable pressor response to each
concentration of U-46619.

Protocol Series 1.2: Evaluate the effect of CH on NO-dependent pulmonary vasodilation
in neonatal rats.

Endothelium-Dependent Vasodilatory Responses. Receptor-mediated
vasodilation to the endothelium-derived NO (EDNO)-dependent vasodilator, AVP (226),
was measured in lungs from control and CH neonatal rats. After a 20 min equilibration
period, lungs were preconstricted with the thromboxane analog, U-46619 to achieve a
stable arterial pressor response of ~10 mmHg. AVP (25 nM) was then added to the
perfusate to induce vasodilation. Parallel protocols were performed in the presence of LNNA to verify the contribution of endogenous NO to this response. Vasodilatory
responses are expressed as a percent reversal of U-46619-mediated constriction.

Responses to Exogenous NO. Considering that EDNO-dependent responses
following CH may be influenced by altered NO bioavailability or VSM sensitivity to NO,
we assessed concentration-response curves to the NO donor, spermine NONOate, in
lungs from each group of rats. After the equilibration period, lungs were preconstricted
with U-46619 to ~10 mmHg above baseline Pa. Once the constriction stabilized, a
cumulative concentration-response curve to spermine NONOate was performed.
Considering that lungs from neonates exposed to CH display greater basal pulmonary
arterial constriction than control lungs, we repeated these experiments in lungs
preconstricted with U-46619 to achieve similar overall Pa between groups. All
experiments were conducted in the presence of L-NNA to eliminate the contribution of
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endogenous NO to these responses. Segmental vascular resistances were evaluated
by double occlusion technique at baseline, after stabilization of the U-46619 constriction,
and following stabilization of the response to each concentration of NONOate.

Protocol Series 1.3: Assess the effect of neonatal CH on expression of pulmonary NOS.
The effect of CH on the expression of NOS isoforms: NOS I (neuronal or nNOS),
NOS II (inducible or iNOS), NOS III (endothelial or eNOS), as well as the posttranslational phosphorylation of eNOS at serine-1177, a modification associated with
increased eNOS-dependent NO production (75), were also investigated. Western blots
were performed using whole lung homogenates from both control and CH neonates as
outlined above in the general western blot protocol. Samples (45 μg protein/lane) were
resolved by SDS-PAGE with 7.5% acrylamide along with molecular-weight standards
(Bio-Rad). Antibodies used to probe for NOS isoforms included mouse monoclonal
antibodies against nNOS (1:500; BD Biosciences-Transduction Labs), iNOS (1:500; BD
Biosciences-Transduction Labs), eNOS (1:1000; BD Biosciences-Transduction Labs),
and phospho(Ser-1177)-eNOS (1:1000; BD Biosciences-Transduction Labs). Protein
expression was normalized to total protein to account for any variance in protein loading.

Protocols for Specific Aim 2
Establish the contribution of ROS to enhanced vasoconstriction in CH-induced
neonatal pHTN.

Protocol Series 2.1: Determine the contribution of ROS to enhanced basal tone and
vasoconstrictor reactivity following CH in isolated (in situ) lungs.
To evaluate the role of ROS in enhanced vasoconstriction following CH, lung
studies similar to those in Protocol Series 1.1 were repeated in the presence of the
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superoxide dismutase (SOD) mimetic, 1-oxyl-2,2,6,6-tetramethyl-4-hydroxypiperidine
(218) (TEMPOL; 1 mM). All lungs were pretreated with L-NNA (300 μM) to avoid
complications of endogenous NO on observed studies. Lungs from P14 neonates in
both groups were allowed to equilibrate for 20 minutes, after which a baseline double
occlusion was performed. The contribution of vascular tone to baseline PVR was
assessed via administration of spermine NONOate. A double occlusion was performed
after stabilization of the response to NONOate. Basal tone is expressed as the change
in resistance to spermine NONOate.
To determine the effect of ROS on vasoconstrictor sensitivity of the pulmonary
vasculature in control and CH pups, a cumulative dose-response curve to U-46619 (50,
100, 150, and 200 nM) was performed in the presence and absence of TEMPOL. A
double occlusion was performed after a stabilized pressor response at each
concentration.

Protocol Series 2.2: Evaluate the role of mitoROS in enhanced pulmonary arterial
vasoconstriction following CH in isolated pulmonary arteries.
We assessed the role of ROS to mediate enhanced pulmonary arterial
vasoconstrictor reactivity in pressurized small pulmonary arteries isolated from each
group of animals (P14) as previously described (44, 197, 242). Pulmonary arteries
[~150-200 μm inner diameter (i.d.)] from the left lung were dissected from surrounding
parenchyma and cannulated on glass microcannulae secured in a vessel perfusion
chamber (Living Systems Instrumentation). Cannulated, pressurized vessels were
superfused with recirculating, heated (37°C) PSS bubbled with a 6% CO2/10%
O2/balance N2 gas mixture for a 20 min equilibration period. Vessel i.d. was
simultaneously measured using bright-field videomicroscopy. Following a 20 min
equilibration period, L-NNA (300 μM) was added to the superfusate. In the presence of
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L-NNA, the vessels developed vasomotor tone. Experiments were allowed to progress
for a minimum of 20 min or until the vasoconstrictor response stabilized. Following
stabilization of basal tone, vessels were superfused with non-recirculating Ca2+-free PSS
that contained (in mM) 129.8 NaCl, 5.4 KCl, 0.83 MgSO4, 19 NaHCO3, 5.5 glucose, and
3 ethylene glycol-bis(β-aminoethyl ether)-N,N,N’N’-tetraacetic acid (EGTA) for 30 min.
Following a 30 min Ca2+-free PSS washout, recirculation was initiated and ionomycin [3
μM; Ca2+ ionophore (198, 243)] was added to maximally dilate the vessel. Basal tone
was expressed as % of maximally dilated, Ca2+-free diameter using the formula: [(Ca2+free i.d. – Constricted i.d.)/Ca2+-free i.d.]*100.
In isolated vessel studies conducted in the presence of ROS inhibitors, the
inhibitor was present throughout the experiment – during the vessel dissection,
cannulation, equilibration, and L-NNA exposure. Basal tone studies were performed in
the presence and absence of the mitochondrial specific SOD mimetic, MitoTEMPO (74)
(200 μM), MitoQ (67, 109, 241) (1 μM; restores electron flux through the electron
transport chain to lower oxidative stress), or vehicle.

Protocols for Specific Aim 3
Define the contribution of PKCβ-signaling to enhanced vascular reactivity
following CH exposure in neonates.

Protocol Series 3.1: Determine the contribution of PKCβ to CH-dependent increases in
vasoconstriction.

Isolated (in situ) lung studies
To evaluate the role of PKCβ to mediate enhanced vasoconstriction following CH,
lung studies similar to those in Protocol Series 2.1 were repeated in the presence of
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either the general PKC inihibitor, Ro 31-8220 (242) (10 μM) or the selective PKCβ
inhibitor LY-333,531 (84, 146, 242) (10 nM). As in Protocol Series 2.1, all lungs were
pretreated with L-NNA (300 μM). Following a 20 minute equilibration period, a baseline
double occlusion was performed in all in situ lung preparations. The contribution of
vascular tone to baseline PVR was assessed through administration of spermine
NONOate. A double occlusion was performed after stabilization of the response to
NONOate. Basal tone is expressed as the change in resistance to spermine NONOate.
To determine the contribution of PKC and PKCβ to vasoconstrictor sensitivity of
the pulmonary vasculature in neonates from both groups, a cumulative dose-response
curve to U-46619 (50, 100, 150, and 200 nM) was performed in the presence and
absence of either Ro 31-8220 (10 μM) or LY-333,531 (10 nM). A double occlusion was
performed after a stabilized pressor response at each concentration.

Isolated pulmonary arteries
Parallel to Protocol Series 2.2, we assessed effects of PKCβ inhibition with LY333,531 on basal tone development in isolated, pressurized pulmonary arteries (~150200 μm i.d.) collected from both control and CH neonates. Similar to Protocol Series 2.2,
cannulated arteries were equilibrated in bubbled PSS for 20 min. Following a 20 min
equilibration period, L-NNA (300 μM) was added to the superfusate. In the presence of
L-NNA, the vessels developed vasomotor tone. Experiments were allowed to progress
for a minimum of 20 min or until the vasoconstrictor response stabilized. Following
stabilization of tone, vessels were superfused with non-recirculating Ca2+-free PSS for
30 min. Following a 30 min Ca2+-free PSS washout, recirculation was initiated and
ionomycin (3 μM) was added to maximally dilate the vessel. Basal tone was expressed
as % of maximally dilated, Ca2+-free diameter using the formula: [(Ca2+-free i.d. –
Constricted i.d.)/Ca2+-free i.d.]*100.
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To evaluate the contribution of PKCβ to arterial tone development, isolated
pulmonary arteries from both control and CH neonates were evaluated in the presence
and absence of LY-333,531 (10 nM). When present, LY-333,531 was maintained
throughout the experimental duration – during the vessel dissection, cannulation,
equilibration, and L-NNA exposure.

Protocol Series 3.2: Determine the effect of PKCβ stimulation on mitoROS generation in
neonatal pulmonary VSM.
PKC-dependent increases in levels of mitochondrial ROS (mitoROS) were
assessed in transiently cultured, primary PASMCs as previously described (208).
Briefly, neonatal rats (P14) from control neonates were anesthetized with pentobarbital
sodium (200 mg/kg i.p.) and the heart and lungs were exposed via midline thoracotomy.
The left and right lungs were removed and placed in sterile 20 mM Ca2+ Hank’s buffered
saline solution (HBSS) plus 1% (v/v) penicillin/streptomycin (pen/strep). Intrapulmonary
arteries (~2nd-5th order) were dissected from surrounding lung parenchyma. To isolate
PASMCs, isolated pulmonary arteries from both lungs were enzymatically digested in 20
mM Ca2+ HBSS containing papain (9.5 U/ml), type-1 collagenase (1,750 U/ml), and
dithiothreitol (1 mM) at 37°C for 15 min. Following enzymatic digestion, collected
pulmonary arteries were added to a 70 μm cell strainer and rinsed with 10 mL Ca2+-free
HBSS. Pulmonary arteries were then added to a fresh Eppendorf tube containing Ca2+free HBSS and dispersed with a Pasteur pipette. The cell suspension was then placed
on gelatin-coated 25 mm glass coverslips and cultured in Ham’s F-12 media
supplemented with 5% fetal bovine serum (FBS) and 1% pen/strep for 48 hrs at 37°C.
Cultured PASMCs from control neonates were serum starved for 24 hours in
Ham’s F-12 media plus 1% FBS and 1% pen/strep prior to experimentation. Cells were
then treated with PMA (10 μM) to stimulate PKC-dependent mitoROS production.
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Mitochondrial-derived O2- was detected with the mitochondrial specific O2- indicator
MitoSOX (147) (5 μM). Depending on the experimental protocol, cells were pre-treated
with scavengers of cellular ROS, 1-oxyl-2,2,6,6-tetramethyl-4-hydroxypiperidine (218)
(TEMPOL; 1 mM) and 4,5-Dihydroxy-1,3-benzenedisulfonic acid disodium salt (145)
(Tiron, 10 mM). A selective scavenger of mitochondrial O2- was also used (2-(2,2,6,6tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride
(mitoTEMPO, 200 μM). ROS scavenger pre-treatment occurred for 20 minutes at 37°C
and remained throughout the duration of mitoSOX treatment. Following 20 min pretreatment, PASMCs were then exposed to mitoSOX for 30 min before being fixed with
4% paraformaldehyde (PFA). The coverslips containing mitoSOX labeled PASMCs
were then secured to a glass slide using FluoroGel (Electron Microscopy Sciences) and
imaged using confocal microscopy.
Fluorescence images were acquired with a x63 80% glycerol immersion objective
on a confocal microscope (Leica, TCS SP5, 1.3 numerical aperture). MitoSOX was
excited with a DPSS 561 laser and the emission processed through an Acousto-Optical
Beam Splitter (AOBS, Leica) crystal set to an emission bandwidth of 570 nm – 620 nm.
Images were obtained without an optical zoom (x-y pixel dimensions of 0.49 μm x 0.49
μm), all images were obtained using a 512 x 512 frame, and frame averaging of 2 scans.
Scan speed was set to 400 Hz. Laser power was 60% for the DPSS 561 laser. Zstacks were obtained at z-steps of 0.8 μm. Detector gain and offset setting were held
constant for all acquired z-stacks at a gain setting of 985 and an offset of -12 for the
photomultiplier tube set to collect bandwidth of 570 nm – 620 nm.
Quantification of fluorescence was performed using SlideBook 6 (3i: Intelligent
Imaging Innovations). MitoSOX fluorescence intensity is represented as an average
fluorescence intensity using an inclusive threshold of 10,000 to 65,535 (maximum for 16
bit images). Each z-stack was thresholded to select for positive-stained areas with
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fluorescence intensity values above background (cells not treated with MitoSOX). Data
are reported as mean ± SEM and n represents the number of individual animals that
yielded cells for experimentation. Each individual n is an average of 2 technical
replicates of cells from the same animal. To explore PKCβ-dependent mitoROS
production, we conducted studies parallel to Protocol Series 2.2, in the presence and
absence of LY-333,531.

Protocol Series 3.3: Assess the effect of neonatal CH on PKCβ expression.
Western blots were performed to evaluate protein expression of PKCβ splice
variants (PKCβI and PKCβII) protein expression in isolated pulmonary arteries from
each group of rats (209, 269). The following primary antibodies were used: α-PKCβI
(1:200, Santa Cruz) and α-PKCβII (1:200, Santa Cruz). Protein expression was
normalized to total protein, as determined by staining with Coomassie, to account for
variance in protein loading.
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CHAPTER 3 – RESULTS
General
Evidence for pHTN and Right Ventricular Hypertrophy in Neonatal CH Rats
CH neonates developed higher RVSP compared to normoxic control rats (Figure
2A, B). Heart rate was not significantly different between groups (Table 1). Consistent
with elevated RVSP, the ratio of RV to LV+S weight was increased by CH exposure,
demonstrating RV hypertrophy indicative of pHTN (Figure 2C). Similar results were
obtained for RV weight normalized to either body weight or total heart weight (Table 1).
CH also increased LV+S weight normalized to body mass, which may reflect a lower
body weight of CH neonates compared to age-matched controls (Table 1). Hematocrit
was greater in rats exposed to CH compared to controls, reflecting the polycythemic
response to CH (Table 1).

Saline gases in isolated (in situ) lung experiments
Effluent collected from both control and CH rats and analyzed by iStat
demonstrtated that pH, PCO2, and P02 did not differ between groups (Table 2).

Specific Aim 1
Determine the contribution of endothelial dysfunction to enhanced basal tone and
agonist-induced vasoconstriction in neonatal pHTN.
Hypothesis:
We hypothesized that neonatal CH enhances basal tone and pulmonary
vasoconstrictor sensitivity by limiting NO-dependent pulmonary vasodilation.

47

Figure 2
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Figure 2. Chronic hypoxia (CH) increases peak right ventricular systolic pressure
(RVSP) and induces RV hypertrophy in neonatal rats.
(A) Sample pressure traces and (B) Summary data for peak RVSP in control and CH
neonates. (C) Ratio of right ventricular (RV) mass to left ventricular plus septal
(LV+S) mass for each group. Values are means ± SEM; n = 4-11/group (indicated in
bars); *p<0.05 vs. control, analyzed by unpaired t-test.
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Table 1

Table 1. Body weight, heart weights, hematocrit, and heart rate from control and CH
neonatal rats.
Values are means ± SEM; n = 4-11 animals/group (indicated in parentheses).
*p<0.05 vs. control; analyzed by unpaired t-test. RV, right ventricle; BW, body weight;
LV+S, left ventricle plus the interventricular septum; Total, total heart weight.
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Table 2

Table 2. Saline gas values from recirculating perfusate of lungs from control and CH
neonates.
Perfusate samples were taken following a 20 min equilibration period. Values are
mean ± SEM with n in parenthesis; n = 11-22/group; analyzed by t-test, no significant
differences between groups.
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Endogenous NO Limits CH-Dependent Increases in Basal Pulmonary Vascular
Resistance
In situ lungs from neonates exposed to CH displayed elevated total and arterial
baseline vascular resistance compared to normoxic controls (Figure 3A, B). In contrast,
venous resistance was unaltered by CH exposure (Figure 3C). L-NNA increased total,
arterial and venous baseline PVR in lungs from CH neonates, while having no effect in
control pups (Figure 3).
The contribution of basal tone to CH-dependent increases in PVR was assessed
by evaluating changes in total and segmental resistances to the NO donor, spermine
NONOate, in lungs from each group. CH increased basal tone (Figure 4A) in the
absence of NOS inhibition. This effect of CH appeared to result from arterial constriction
since changes in arterial resistance to spermine NONOate tended to be greater in lungs
from CH rats compared to controls (Figure 4B), although this response did not reach
statistical significance. NOS inhibition increased basal pulmonary vascular tone in CH
rats (Figure 4A) by further augmenting arterial constriction (Figure 4B), while having no
significant effect in control lungs. In contrast, venous tone was minimal and unaltered by
either CH exposure or treatment with L-NNA (Figure 4C).

Endogenous NO Attenuates U-46619-Induced Pulmonary Vasoconstriction
In addition to effects of CH to increase basal tone (Figure 4), total, arterial and
venous constrictor responses to U-46619 were greater in lungs from CH compared to
normoxic neonates in the absence of NOS inhibition (Figure 5). L-NNA markedly
augmented vasoconstrictor reactivity to U-46619 in lungs from CH rats, while having a
more modest effect in control lungs. Enhanced vasoconstrictor sensitivity to U-46619
following CH was primarily a function of greater arterial constriction (Figure 5B), as
venous responses to U-46619 were minimal (Figure 5C).
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Figure 3. Endogenous NO limits CH-dependent increases in baseline pulmonary
vascular resistance.
(A) total, (B) arterial, and (C) venous baseline vascular resistances in lungs (in situ)
from control and CH neonatal rats in the presence or absence of the NOS inhibitor LNNA (300 μM). Values are means ± SEM; n = 6-10/group (indicated in bars);
*p<0.05 vs. control, #p<0.05 vs. vehicle, analyzed by two-way ANOVA followed by
Student-Newman-Keuls post-hoc comparison.
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Figure 4. Endogenous NO limits CH-dependent increases in basal pulmonary arterial
tone.
The contribution of basal tone to (A) total, (B) arterial and (C) venous resistance is
expressed as the change in resistance to spermine NONOate (100 μM) in lungs (in
situ) from control and CH neonates. Experiments were conducted in the presence or
absence of L-NNA (300 μM). Values are means ± SEM; n = 6-10/group (indicated in
or above bars); *p<0.05 vs. control, #p<0.05 vs. vehicle, analyzed by two-way
ANOVA followed by Student-Newman-Keuls post-hoc comparison.
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Figure 5. Endogenous NO limits CH-dependent increases in vasoconstrictor
sensitivity to U-46619.
Changes in (A) total, (B) arterial, and (C) venous resistance to U-46619 in lungs (in
situ) from control and CH neonates. Experiments were conducted in the presence or
absence of L-NNA (300 μM). Values are means ± SEM; n = 8 for Control Vehicle, n =
10 for CH Vehicle, n = 9 for Control L-NNA, n = 9 for CH L-NNA; *p<0.05 vs. control,
#p<0.05 vs. vehicle; analyzed by two way ANOVA at each concentration of U-46619
followed by Student-Newman-Keuls post-hoc comparison.
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CH Augments EDNO-Dependent Pulmonary Vasodilation
Lungs from control and CH neonates were preconstricted with a concentration of
U-46619 sufficient to achieve similar pressor responses between groups (Table 3) and
then treated with AVP to dilate the pulmonary circulation. Vasodilatory responses to
AVP were greatly augmented following exposure to CH (Figure 6A). L-NNA nearly
abolished AVP-induced pulmonary vasodilation in lungs from each group demonstrating
that this response depends on NOS-derived NO.

CH Does Not Alter Vasodilatory Responsiveness to Exogenous NO
In contrast to effects of CH to augment EDNO-dependent vasoreactivity (Figure
6A), vasodilatory responses to exogenous NO (spermine NONOate) in L-NNA pretreated lungs were not different between lungs from control and CH neonatal rats
(Figure 6B). Similar responses to spermine NONOate were observed whether U-46619
was added to achieve similar changes in PVR or total PVR between groups (Table 4).

CH Increases levels of Pulmonary eNOS as well as Serine-1177-Phosphorylated
eNOS
Both total eNOS and the ratio of Ser-1177 phosphorylated eNOS to total eNOS
were greater in lung samples from CH neonates compared to controls (Figure 7) as
determined by western blotting. In contrast, CH had no significant effect on pulmonary
nNOS or iNOS levels (Figure 8).
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Table 3

Table 3. Pulmonary vascular resistance values for lungs from control and CH
neonates treated with AVP in the presence or absence of LNNA.
When indicated, 300 μM L-NNA present throughout experiment. Units of resistance
(R) are mmHg ꞏml-1ꞏkgꞏmin. Values are means ± SEM with n in parenthesis; n = 514/group; *p<0.05 vs. control, #p<0.05 vs. vehicle; analyzed by two way ANOVA,
individual groups were further evaluated using a Student-Newman-Keuls post-hoc
comparison.
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Figure 6. CH augments EDNO-dependent vasodilation to arginine vasopressin (AVP)
without altering smooth muscle sensitivity to NO.
A. Total vasodilatory responses (percent reversal of U-46619-induced constriction) to
AVP (25 nM) in lungs (in situ) from control and CH neonates. Experiments were
conducted in the presence or absence of L-NNA (300 μM). Values are means ± SEM;
n = 5-14/group (indicated in or below bars); *p<0.05 vs. control, #p<0.05 vs. vehicle,
analyzed by two way ANOVA followed by Student-Newman-Keuls post-hoc
comparison. B. Total vasodilatory responses (percent reversal of U-46619-induced
constriction) to spermine NONOate. Experiments were conducted in the presence of
L-NNA to limit the contribution of endogenous NO production. Values are means ±
SEM; n = 5 for Control, n = 5 for CH; analyzed by two way ANOVA.
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Table 4

Table 4. Pulmonary vascular resistance values for lungs from control and CH
neonates treated with NONOate.
300 μM L-NNA present throughout experiment. Left side of table shows data from
lungs with [U-46619] sufficient to raise baseline pulmonary arterial pressure by 10
mmHg in both groups. Right side of table shows data from lungs with [U-46619] to
equalize baseline pulmonary arterial pressure between groups. Units of resistance
(R) are mmHg ꞏml-1ꞏkgꞏmin. Values are means ± SEM with n in parenthesis; n = 514/group; *p<0.05 vs. control; analyzed by unpaired t-test.
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Figure 7
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Figure 7. CH increases levels of eNOS and phosphorylated eNOS (Ser-1177) in
neonatal rat lungs.
(A) Western blots for eNOS and phospho-eNOS, and (B, C) summary data for total
eNOS and the ratio of phosphorylated eNOS to total eNOS in lungs from control and
CH neonatal rats. Values are means ± SEM; n = 6/group (indicated in bars); *p<0.05
vs. control, analyzed by unpaired t-test.
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Figure 8
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Figure 8. CH does not alter iNOS or nNOS protein expression in neonatal lungs.
(A) Western blots and (B, C) summary data for total iNOS and nNOS in lungs from
neonatal control and CH rats. n = 6/group (indicated in bars), analyzed by unpaired ttest.
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Specific Aim 2
Establish the contribution of ROS to enhanced vasoconstriction in CH-induced
neonatal pHTN.

Hypothesis:
We hypothesized that mitoROS contribute to enhanced basal and agonistinduced pulmonary arterial constriction in neonates with CH-induced pHTN.

ROS Facilitate Augmented Basal Pulmonary Arterial Tone Following CH
To eliminate the contribution of endogenous NO on observed pulmonary vascular
tone, this study and all subsequent isolated (in situ) lung studies were done in the
continued presence of L-NNA. CH-dependent increases in baseline PVR were fully
relieved by TEMPOL (Figure 9A). Furthermore, TEMPOL normalized arterial resistance
in lungs from both control and CH groups while neither CH nor TEMPOL altered venous
resistance (Figure 9B, C). This result suggested that the CH-induced elevation in
baseline PVR was due entirely to the effect of CH to increase arterial resistance.
To evaluate the contribution of basal tone to CH-dependent elevations in PVR,
we assessed vasodilatory responses to the NO donor, spermine NONOate. Exposure of
neonatal rats to CH lead to an elevation in basal tone, due to greater pulmonary arterial
tone (Figure 10A, B). Pre-treatment with the SOD mimetic, TEMPOL prevented CHdependent increases in basal tone and pulmonary vascular tone was normalized
between control and CH neonates (Figure 10A). This finding suggested that augmented
PVR observed following neonatal CH exposure was completely due to mechanisms of
increased vasoconstriction.
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Figure 9. CH increases baseline pulmonary vascular resistance through ROS
signaling.
(A) total, (B) arterial, and (C) venous baseline vascular resistances in lungs (in situ)
from control and CH neonatal rats in the presence or absence of the SOD mimetic
TEMPOL (1 mM). Experiments were conducted in the presence of L-NNA (300 μM).
Values are means ± SEM; n = 4-10/group (indicated in bars); *p<0.05 vs. control,
#p<0.05 vs. vehicle, analyzed by two-way ANOVA followed by Student-NewmanKeuls post-hoc comparison.
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Figure 10. ROS contribute to augmented basal tone in lungs from neonatal rats
exposed to CH.
The contribution of basal tone to (A) total, (B) arterial and (C) venous resistance is
expressed as the change in resistance to spermine NONOate (100 μM) in lungs (in
situ) from control and CH neonates. Experiments were conducted in the presence of
L-NNA (300 μM) with or without the ROS scavenger, TEMPOL (1 mM). Values are
means ± SEM; n = 4-10/group (indicated in or above bars); *p<0.05 vs. control,
#p<0.05 vs. vehicle, analyzed by two way ANOVA with a Student-Newman-Keuls
post-hoc test.
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ROS Mediate Enhanced Vasoconstrictor Sensitivity to U-46619 Following CH
Exposure
U-46619 produced concentration-dependent increases in total PVR in lungs from
both control and CH neonates (Figure 11A). This effect of U-46619 was largely a result
of arterial constriction (Figure 11B), as venous responses were relatively small in lungs
from both groups of rats (Figure 11C).
Vasoconstrictor reactivity to U-46619 was significantly augmented by CH (Figure
11A) Neonatal pHTN induced by exposure to CH elevates vasoreactivity to U46619
(Figure 11A). This response to CH was primarily a function of increased arterial
reactivity to U-46619 (Figure 11B), although venoconstriction to U-46619 was also
augmented by CH exposure (Figure 11C). TEMPOL attenuated total, arterial and venous
responses to U-46619 in lungs from CH rats (Figure 11A, B, C). Although TEMPOL also
tended to reduce vascular reactivity to U46619 in control lungs, this effect did not
achieve statistical significance (Figure 11). These findings suggest that O2- contributes
to elevated pulmonary vasoconstrictor sensitivity to U46619 following neonatal CH.

MitoROS Contribute to Enhanced Pulmonary Arterial Tone Following CH
Exposure to CH lead to greater pulmonary arterial tone in isolated, pressurized
pulmonary arteries collected from control and CH neonates (Figure 12, 13, and 14).
Pretreatment with either the mitochondrial selective O2- scavenger MitoTEMPO or the
inhibitor of mitoROS production, MitoQ, eliminated the CH-dependent increase in arterial
tone. There was no significant effect of either MitoTEMPO of MitoQ to alter tone in
vessels from control neonates (Figures 13 and 14). Ca2+-free inner and outer diameters
for pulmonary arteries included in this study are listed in Tables 5 and 6. Taken
together, these results support a major contribution of mitoROS to mediate enhanced
pulmonary arterial tone in neonatal rats exposed to CH.
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Figure 11. ROS facilitate enhanced vasoconstrictor sensitivity in lungs from CH
neonates.
Changes in (A) total, (B) arterial, and (C) venous resistance to U-46619 in lungs from
control and CH neonates. Experiments were conducted in the continued presence of
L-NNA (300 μM) with or without the ROS scavenger, TEMPOL (1 mM). Values are
means ± SEM; n = 6 for Control Vehicle, n = 5 for CH Vehicle, n = 6 for Control
TEMPOL, n = 4 for CH TEMPOL; *p<0.05 vs. control, #p<0.05 vs. vehicle; analyzed
by two way ANOVA at each [U-46619] with a Student-Newman-Keuls post-hoc
comparison.
65

Figure 12
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Figure 12. CH increases basal tone development in isolated, small pulmonary
arteries from neonatal rats.
Representative pressure traces from control and CH groups showing arterial tone
development in the presence of LNNA (300 μM) following 20 min equilibration period.
Arrow indicates pausing of data acquisition to allow for 30 min Ca2+-free PSS
washout followed by 30 min in Ca2+-free PSS + ionomycin (3 μM).
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Figure 13
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Figure 13. MitoROS contribute to increased basal tone isolated pulmonary arteries
from CH neonates.
Vasoconstriction is % maximally dilated (Ca2+-free) diameter, calculated using the
formula: [(Ca2+-free i.d. – Constricted i.d.)/Ca2+-free i.d.]. Experiments were
conducted in the continued presence of MitoTEMPO, (200 μM). The vessel was
superfused with L-NNA (300 μM) following 20 min equilibration time. Values are
means ± SEM; n = 5-6/group (indicated in bars); *p<0.05 vs. control, #p<0.05 vs.
vehicle, analyzed by two way ANOVA followed by Student-Newman-Keuls post-hoc
test.
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Figure 14
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Figure 14. MitoROS contribute to increased basal tone in isolated pulmonary arteries
from CH neonates.
Vasoconstriction is % maximally dilated (Ca2+-free) Diameter, calculated using the
formula: [(Ca2+-free i.d. – Constricted i.d.)/Ca2+-free i.d.]. Experiments were
conducted in the continued presence of MitoQ, (1 μM, restores electron flux through
the electron transport chain to lower oxidative stress). The vessel was superfused
with L-NNA (300 μM) following 20 min equilibration time. Values are means ± SEM;
n = 8-10/group (indicated in bars); *p<0.05 vs. control, #p<0.05 vs. vehicle, analyzed
by two way ANOVA followed by Student-Newman-Keuls post-hoc test.
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Table 5

Table 5. Ca2+-free diameters for isolated pulmonary arteries from both control and
CH neonates ± MitoTEMPO.
Values are mean ± SEM with n in parenthesis; n = 5-6/group; analyzed by two way
ANOVA followed by Student-Newman-Keuls post-hoc test, no significant differences
between groups.
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Table 6

Table 6. Ca2+-free diameters for isolated pulmonary arteries from both control and
CH neonates ± MitoQ.
Values are mean ± SEM with n in parenthesis; n = 8-10/group; *p<0.05 vs. control;
analyzed by two way ANOVA followed by Student-Newman-Keuls post-hoc test.
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Specific Aim 3
Define the contribution of PKCβ-signaling to enhanced vascular reactivity
following CH exposure in neonates.
Hypothesis:
PKCβ-dependent mitoROS generation in pulmonary vascular smooth muscle
contributes to enhanced pulmonary arterial tone following neonatal CH.

PKCβ Contributes to Enhanced Pulmonary Arterial Vasoconstriction in Lungs from
Neonates Exposed to CH
Pretreatment with PKC inhibitor Ro 31-8220 did not significantly reduce baseline
PVR in lungs from CH neonates (Figure 15A), however PKCβ inhibition did significantly
lower augmented baseline PVR (Figure 17A). CH-dependent increases in arterial
resistance were significantly limited by either PKC or PKCβ inhibition (Figure 15B and
17B), suggesting that PKC and PKCβ signaling contribute to increased pulmonary
arterial resistance following CH exposure. Neither CH nor PKC inhibitors altered venous
resistance (Figure 15C and 17C) demonstrating that changes in arterial resistance
following CH exposure are responsible for elevated baseline PVR in neonates exposed
to CH.
The general PKC inhibitor, Ro 31-8220, attenuated CH-dependent increases in
basal pulmonary arterial tone (Figure 16) as well as U-46619-induced vasoconstriction
(Figure 19). Ro 31-8220 limited CH-dependent increases in both basal and U-46619dependent changes in arterial tone (Figures 16 and 19). Pretreatment with LY-333,531
significantly reduced pulmonary arterial tone and agonist-induced vasoconstriction to U46619 in lungs from CH neonates (Figure 18 and 20). Neither PKC nor PKCβ inhibition
altered basal tone or pulmonary vasoreactivity to U-46619 in lungs from control
neonates (Figure 16, 18, 19, and 20). Collectively, these findings suggest that PKCβ
71

A

Total Vascular Resistance
-1
(mmHgꞏml ꞏkgꞏmin)

Figure 15

0.6
0.5

Control
CH

*
*

0.4
0.3
0.2
0.1
0.0

6

13

6

9

Vehicle Ro 31-8220
0.6

Arterial Resistance
(mmHgꞏml-1ꞏkgꞏmin)

B

*

0.5
0.4

*#

0.3
0.2
0.1
0.0

6

13

6

9

Vehicle Ro 31-8220
0.6

Venous Resistance
(mmHgꞏml-1ꞏkgꞏmin)

C

0.5
0.4
0.3
0.2
0.1
0.0

6

13

6

9

Vehicle Ro 31-8220

Figure 15. CH increases baseline pulmonary arterial resistance through PKC
signaling.
(A) total, (B) arterial, and (C) venous baseline vascular resistances in lungs (in situ)
from control and CH neonatal rats in the presence or absence of the PKC inhibitor Ro
31-8220 (10 μM). Experiments were conducted in the presence of L-NNA (300 μM).
Values are means ± SEM; n = 6-13/group (indicated in bars); *p<0.05 vs. control,
#p<0.05 vs. vehicle, analyzed by two-way ANOVA followed by Student-NewmanKeuls post-hoc comparison.
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Figure 16. PKC contributes to augmented basal tone in lungs from neonatal rats
exposed to CH.
The contribution of basal tone to (A) total, (B) arterial and (C) venous resistance is
expressed as the change in resistance to spermine NONOate (100 μM) in lungs (in
situ) from control and CH neonates. Experiments were conducted continued
presence of L-NNA (300 μM) with or without the PKC inhibitor, Ro 31-8220 (10 μM).
Values are means ± SEM; n = 6-13/group (indicated in or above bars); *p<0.05 vs.
control, #p<0.05 vs. vehicle, analyzed by two way ANOVA with a Student-NewmanKeuls post-hoc test.
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Figure 17. CH increases baseline pulmonary vascular resistance through PKCβ
signaling.
(A) total, (B) arterial, and (C) venous baseline vascular resistances in lungs (in situ)
from control and CH neonatal rats in the presence or absence of the PKCβ inhibitor
LY-333,531 (10 nM). Experiments were conducted in the presence of L-NNA (300
μM). Values are means ± SEM; n = 6-13/group (indicated in bars); *p<0.05 vs.
control, #p<0.05 vs. vehicle, analyzed by two-way ANOVA followed by StudentNewman-Keuls post-hoc comparison.
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Figure 18. PKCβ inhibition limits CH-dependent increases in basal tone in lungs from
neonatal rats.
The contribution of basal tone to (A) total, (B) arterial and (C) venous resistance is
expressed as the change in resistance to spermine NONOate (100 μM) in lungs (in
situ) from control and CH neonates. Experiments were conducted continued
presence of L-NNA (300 μM) with or without the PKCβ inhibitor, LY-333,531 (10 nM).
Values are means ± SEM; n = 4-11/group (indicated in or above bars); *p<0.05 vs.
control, #p<0.05 vs. vehicle, analyzed by two way ANOVA with a Student-NewmanKeuls post-hoc test.
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Figure 19. PKC facilitates enhanced vasoconstrictor sensitivity in lungs from CH
neonates.
Changes in (A) total, (B) arterial, and (C) venous resistance to U-46619 in lungs from
control and CH neonates. Experiments were conducted in the continued presence of
L-NNA (300 μM) with or without the PKC inhibitor, Ro 31-8220 (10 μM). Values are
means ± SEM; n = 5 for Control Vehicle, n = 6 for CH Vehicle, n = 5 for Control Ro
31-8220, n = 4 for CH Ro 31-8220; *p<0.05 vs. control, #p<0.05 vs. vehicle, analyzed
by two way ANOVA at each [U-46619] with a Student-Newman-Keuls post-hoc test.
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Figure 20. PKCβ facilitates enhanced vasoconstrictor sensitivity in lungs from CH
neonates.
Changes in (A) total, (B) arterial, and (C) venous resistance to U-46619 in lungs from
control and CH neonates. Experiments were conducted in the continued presence of
L-NNA (300 μM) with or without the PKCβ inhibitor, LY-333,531 (10 nM). Values are
means ± SEM; n = 6 for Control Vehicle, n = 5 for CH Vehicle, n = 5 for Control LY333,531, n = 5 for CH LY-333,531; *p<0.05 vs. control, #p<0.05 vs. vehicle, analyzed
by two way ANOVA at each [U-46619] with a Student-Newman-Keuls post-hoc test.
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contributes to enhanced pulmonary arterial tone and pulmonary arterial vasoconstrictor
sensitivity to U-46619 in neonates with CH-induced pHTN.

PKCβ Mediates CH-induced Basal Tone in Isolated Pulmonary Arteries
Consistent with effects of LY-333,531 to reduce CH-dependent increases in
basal tone in the in situ lung preparation, PKCβ inhibition reduced basal tone
development in isolated, pressurized pulmonary arteries from CH rats (Figure 21). We
also observed no effect of PKCβ inhibition on basal tone in arteries from normoxic control
neonates (Figure 21). Inner and outer Ca2+-free diameters of vessels included in this
study are listed in Table 7.

PMA Stimulates mitoROS Production in a PKCβ-Dependent Manner in Isolated
PASMCs from Control Neonates
In transiently cultured PASMCs collected from pulmonary arteries of control
neonatal rats, we evaluated PKCβ-dependent mitoROS production using the PKC
activator, PMA to simulate an increase in mitochondrial O2- production assessed by
fluorescence of the mitochondrial selective O2- indicator, MitoSOX. Upon stimulation
with PMA, we observed that MitoSOX fluorescence increased in a manner sensitive to
either PKCβ inhibition with LY-333,531 or O2- scavenging via either TEMPOL or tiron
(Figure 22). MitoTEMPO similarly prevented PMA-mediated increases in mitoROS
generation (Figure 22). These inhibitors were without effect on MitoSOX fluorescence in
the absence of PMA treatment (Figure 22).

PKCβ Protein Expression in lungs from neonatal control and CH rats
Western blot analysis revealed protein expression of both PKC βI or PKC βII
isoforms in lungs from each group of rats (Figure 23). Although levels of each isoform
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Figure 21. PKCβ contributes to increased basal tone in isolated pulmonary arteries
from CH neonates.
Vasoconstriction is % maximally dilated (Ca2+-free) diameter, calculated using the
formula: [(Ca2+-free i.d. – Constricted i.d.)/Ca2+-free i.d.]. Experiments were
conducted in the continued presence of PKCβ inhibitor, LY-333,531 (10 nM). The
vessel was superfused with L-NNA (300 μM) following 20 min equilibration time.
Values are means ± SEM; n = 5-10/ group (indicated in bars); *p<0.05 vs. control,
#p<0.05 vs. vehicle, analyzed by two way ANOVA followed by Student-NewmanKeuls post-hoc test.
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Table 7

Table 7. Ca2+-free diameters for isolated pulmonary arteries from both control and
CH neonates ± LY-333,531.
Values are mean ± SEM with n in parenthesis; n = 5-10/group; *p<0.05 vs. control,
#p<0.05 vs. vehicle; analyzed by two way ANOVA followed by Student-NewmanKeuls post-hoc test.
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Figure 22. PKCβ signaling leads to mitoROS production in PASMCs from control
neonates.
(A) Representative photomicrographs of mitoSOX fluorescence from transiently
cultured PASMCs collected from pulmonary arteries of control neonates. (B)
Summary data for 6 biological replicates for each treatment condition. Values are
means ± SEM; n = 6/group (indicated in bars), analyzed by two way ANOVA followed
by Student-Newman-Keuls post-hoc test.
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Figure 23. CH does not significantly alter levels of PKC βI and PKC βII in neonatal
rat lungs.
(A) Western blots for PKC βI and PKC βII, and (B, C) summary data for PKC βI and
PKC βII normalized to total protein as assessed via Coomassie staining in pulmonary
arteries from control and CH neonatal rats. Values are means ± SEM; n = 6/group
(indicated in bars), analyzed by unpaired t-test.
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tended to be greater in lungs from CH compared to control neonates, this effect did not
achieve statistical significance.
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CHAPTER 4 - DISCUSSION

Specific Aim 1: Determine the contribution of endothelial dysfunction to enhanced
basal tone and agonist-induced vasoconstriction in neonatal pHTN.

Vasoconstrictor mechanisms play an important role in the development of CHinduced neonatal pHTN (15, 40, 91, 129). However, whether vasoconstriction in this
setting is a consequence of diminished endothelium-dependent vasodilatory capacity,
enhanced production of a contractile factor, or an inherent increase in VSM contractility
is poorly understood. Considering that endothelial dysfunction is implicated in the
development of neonatal pHTN (89, 129), the present aim examined the hypothesis that
neonatal CH enhances basal tone and pulmonary vasoconstrictor sensitivity by limiting
NO-dependent pulmonary vasodilation. The major findings from this aim are that 1)
neonatal CH enhances both basal pulmonary arterial tone and agonist-induced
vasoconstrictor sensitivity; 2) endogenous NO limits these responses to CH, while
having little to no effect in lungs from normoxic control animals; 3) CH augments
receptor-mediated, EDNO-dependent pulmonary arterial dilation, but is without effect on
vasoreactivity to exogenous NO; and 4) CH increases pulmonary expression of eNOS
as well as eNOS phosphorylation at Ser-1177, a post-translational modification
associated with enhanced NO generation (75). Collectively, these data demonstrate an
effect of CH to enhance both basal pulmonary arterial tone and receptor-mediated
vasoconstrictor sensitivity despite a compensatory increase in eNOS expression and
activity.
Exposure to CH leads to neonatal pHTN in a variety of animals models (40, 87,
148) by elevating PVR through increased basal arterial tone and augmented reactivity to
endogenous vasoconstrictor agonists (15, 40, 233). Direct evidence supporting an
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important contribution of vasoconstriction to this response includes findings that ROK
inhibition (180) or inhaled NO (81) acutely reverse PVR in neonatal CH rats.
Furthermore, pulmonary vasoconstrictor sensitivity to serotonin is enhanced in newborn
lambs housed at high altitude (3801 meters) relative to low altitude (335 meters) lambs
in a manner sensitive to ROK inhibition (40). Following exposure to chronic normobaric
hypoxia in neonatal piglets, endothelium-derived thromboxane products lead to
pulmonary arterial vasoconstriction that is absent in normoxic controls (91). In a
neonatal lamb model of pHTN that involves banding of the ductus arteriosus acute
increases in pulmonary blood flow lead to vasoconstriction in a manner consistent with a
myogenic response (250). Although enhanced pulmonary vasoconstriction in the setting
of neonatal pHTN may be due to enhanced production of and sensitivity to endogenous
vasoconstrictor agonists, there is also evidence for diminished production of
endothelium-derived relaxing factors as well (87, 238). However, the relative
contributions of diminished endothelium-dependent vasodilation and increased VSM
contractile responsiveness to the vasoconstrictor component of neonatal pHTN is not
well defined.
One potential mechanism by which neonatal pHTN may occur is through
limitation of the normal NO-dependent fall in PVR. During gestation, the fetal pulmonary
circulation is marked by high resistance to pulmonary blood flow that is maintained by
hypoxic pulmonary vasoconstriction (246). At birth, the increase in O2 tension stimulates
pulmonary arterial eNOS-dependent vasodilation that relieves fetal pulmonary arterial
tone (4, 102). However, even after delivery, the pulmonary circulation retains residual
arterial tone that can be uncovered by eNOS inhibition. For example, in studies using
isolated, perfused lungs from neonatal rats, acute administration of L-NNA increased
baseline PVR by three fold, with the majority of the response in the pulmonary arterial
circulation (53). Furthermore, occlusion of the ductus arteriosus in neonatal lambs
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following NOS inhibition leads to an increase in PVR in a manner consistent with a
myogenic response (251). NO-dependent pulmonary vasodilation is an important
mediator of the transition from high resistance fetal to low resistance antenatal
pulmonary circulation. Therefore, enhanced vasoconstriction may occur in neonatal
pHTN though reduction in NO-dependent vasodilatory capacity.
As mentioned above, neonatal pHTN is often associated with reduced NOdependent vasodilatory responsiveness, which has been attributed to both endothelial
dysfunction and impaired VSM sensitivity to NO. In neonatal lambs with pHTN,
pulmonary eNOS levels are reduced (238) and expression of PDE5 in the pulmonary
circulation is elevated (37). Increased protein expression of PDE5 can limit the
vasodilatory effect of NO in the setting of neonatal pHTN due to disruption of the
signaling cascade of NO (37). In animal models of CH-induced neonatal pHTN, NO and
eNOS levels are also diminished (52, 87, 129). Given evidence for endothelial
dysfunction in the setting of neonatal pHTN, the purpose of the present study was to
address whether neonatal CH elevates PVR through a similar mechanism related to
diminished NO-dependent pulmonary vasodilation.
Our present findings demonstrate that, in contrast to the evidence in the literature
of diminished NO-dependent pulmonary vasodilation, CH exposure enhanced EDNOdependent vasodilation in the pulmonary circulation of newborn rats. In this aim, we
observed increased basal tone and vasoconstrictor sensitivity to U-46619 in lungs from
neonatal CH rats that was greatly enhanced following inhibition of NOS, supporting an
effect of endogenous NO to limit CH-dependent vasoconstriction. In addition, the
majority of the CH-dependent increases in PVR resulted from arterial constriction as
determined by double occlusion technique. These results suggest that neonatal CH
preferentially impacts arterial function, perhaps by increasing arterial smooth muscle
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contractility due to enhanced Ca2+-dependent mechanisms (250) and/or by enhancing
Ca2+ sensitivity via ROK-dependent signaling (180, 262).
Consistent with effects of NOS inhibition to markedly augment basal tone and
agonist-induced arterial constriction following neonatal CH, we found that CH also
augments endogenous NO-dependent pulmonary vasodilation to AVP while having no
effect on reactivity to the NO donor, spermine NONOate. These findings suggest that
CH augments EDNO-dependent pulmonary vasodilation without altering responsiveness
to exogenous NO, and are consistent with previous observations in adult rats from our
group and others that CH selectively increases pulmonary arterial eNOS expression and
enhances NO-dependent pulmonary vasodilation (62, 224, 226, 237).
Our study further suggests a potential mechanism by which CH elevates
endogenous NO production through CH-dependent increases in protein expression of
eNOS as well as levels of phosphorylated eNOS at Ser-1177, while having no
detectable effect on levels of nNOS or iNOS. The lack of CH-dependent changes in
iNOS protein expression is interesting considering that iNOS is a hypoxia-inducible gene
(200) and increased in lungs from adult rats exposed to CH (63, 225). However, in
isolated, pressurized pulmonary arteries from neonatal piglets exposed to either CH or
normoxia, selective iNOS inhibition with aminoguanidine had no effect on baseline
arterial diameter in arteries from either group suggesting that iNOS does not play a role
in regulation of baseline tone in the neonatal pulmonary circulation (87).
The mechanism by which CH increases pulmonary eNOS expression and Ser1177 phosphorylation is not clear, but may result from increased arterial shear stress
associated with CH exposure (253). Ser-1177 phosphorylation of eNOS occurs mainly
due to activity of the serine/threonine kinase, Akt (75). Akt-dependent Ser-1177
phosphorylation of eNOS is increased by shear stress on endothelial cells in vitro (220)
and shear stress increases eNOS mRNA and protein expression in fetal lambs (35).
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Our findings of enhanced endothelium-dependent pulmonary vasodilation and
associated increases in eNOS protein expression/Ser-1177 phosphorylation differ from
previous reports of diminished NO-dependent pulmonary vasodilation in neonatal pHTN
(37, 87). Some of this difference could be attributable to study design as well as species
difference. Whereas the present study employed a CH model of pHTN involving chronic
exposure to hypobaric hypoxia, others have studied effects chronic exposure to
normobaric hypoxia (19, 148) or occlusion of the ductus arteriosus (9, 181). Other
reports describe pulmonary endothelial dysfunction in response to chronic hypobaric
hypoxia in alternate species, including piglets (87) or lambs (40), suggesting a possible
species difference in the neonatal response to hypobaric CH.
Effects of neonatal CH to augment basal and agonist-induced vasoconstriction
following NOS blockade may be explained by an increase in intrinsic VSM contractility or
possibly greater sensitivity to endogenous contractile factors. In neonatal piglets
exposed to CH, endothelium-derived thromboxane products contribute to pulmonary
vasoconstriction (91). Additionally, in neonatal lambs with pHTN, Ca2+ influx through
voltage-gated Ca2+ channels facilitates a myogenic response (250). Furthermore,
enhanced Ca2+ entry via a store-operated mechanism contributes to vasoconstriction In
adult mice with CH-induced pHTN (166, 195, 271). In addition to Ca2+-dependent
mechanisms of enhancing pulmonary VSM contractility, ROK-induced myofilament Ca2+
sensitization has been implicated in both the fetal pulmonary myogenic response (262)
and in mediating enhanced vasoconstrictor reactivity in neonatal pHTN (40, 180, 287).
Similar effects of ROK-dependent Ca2+ sensitization contribute to enhanced VSM
contractility and pressure-dependent tone in lungs from adult CH rats (44, 145).
The literature also points to a potential role for ROS in enhanced pulmonary
vasoconstrictor sensitivity in neonatal pHTN. Levels of ROS resulting from NADPH
oxidase (73), xanthine oxidase (142), uncoupled eNOS (159), and mitochondria (9) are
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elevated in models of neonatal pHTN. ROS-signaling has additionally been linked to
increases in ROK-dependent Ca2+ sensitization (145). Although not directly tested,
ROS-induced ROK-dependent Ca2+ sensitization may play a role in mediating enhanced
VSM contractility and subsequent augmentation of pulmonary arterial vasoconstrictor
sensitivity in the setting of neonatal pHTN.
In conclusion, this aim demonstrates a previously undescribed effect of neonatal
CH to augment both basal pulmonary arterial tone and receptor-mediated
vasoconstrictor sensitivity despite a compensatory increase in NO-mediated pulmonary
vasodilation, eNOS expression and activity. These results advance our understanding of
protective mechanisms that may limit the severity of neonatal pHTN, and are consistent
with an effect of CH to increase basal VSM tone and contractile responsiveness rather
than to impair endothelium-dependent vasodilation.

Specific Aim 2: Establish the role of ROS in enhanced vasoconstriction in the
setting of pHTN in neonates exposed to CH.

Studies in Aim 1 argue against a role for impaired EDNO-dependent pulmonary
vasodilation in mediating augmented vasoconstrictor sensitivity following CH in neonatal
rats. Considering that lung levels of cellular and mitochondrial-derived ROS are elevated
in neonates with pHTN (10, 43, 142) and that ROS contribute to enhanced arterial
vasoconstriction in the hypertensive neonatal pulmonary circulation (43, 145, 197), the
present aim examined the hypothesis that mitoROS contribute to enhanced pulmonary
arterial vasoconstriction in neonates with CH-induced pHTN. The major findings from
this aim are that 1) CH-dependent increases in basal and agonist-induced
vasoconstrictor reactivity rely on ROS and 2) mitochondrial O2- augments pulmonary
arterial tone following neonatal CH exposure. Taken together, these data demonstrate
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an effect of CH to enhance both basal pulmonary arterial tone and receptor-mediated
vasoconstrictor sensitivity in a mitoROS dependent manner. Additionally, the
normalization of baseline total vascular and arterial resistance between lungs from
control and CH neonates after TEMPOL pretreatment suggests that CH-dependent
increases in PVR are due entirely to mechanisms of pulmonary arterial vasoconstriction,
independent of remodeling effects.
Our data suggest that a specific ROS species, O2-, is responsible for mediating
enhanced pulmonary vasoconstriction in neonates with pHTN. In this aim, we used both
TEMPOL and MitoTEMPO to scavenge pulmonary ROS. Both TEMPOL and
MitoTEMPO are SOD mimetics meaning that they convert O2- to H2O2 (74, 161).
Lowering lung levels of O2- correlating with reductions in elevated pulmonary
vasoconstrictor sensitivity in neonates with pHTN has been demonstrated in the
literature (43, 73, 82, 142), however those studies focused on the restoration of NOdependent pulmonary vasodilation. Elevated vascular levels of O2- can scavenge and
therefore limit the bioavailability of NO (43, 82). In this aim, all experiments were done in
the presence of L-NNA to inhibit endogenous NO production. We observed that pretreatment of lungs with TEMPOL abolishes CH-dependent increases in pulmonary
arterial tone. This finding is consistent with an interpretation that O2- potentiates
pulmonary vasoconstriction at the level of the VSM, perhaps by increasing contractility.
Indeed, in adult rodents with CH-induced pHTN, increased levels of pulmonary arterial
O2- activates RhoA/ROK-dependent myofilament Ca2+ sensitization and promotes
pulmonary arterial pressure-dependent tone and enhanced vasoconstrictor sensitivity
(44, 145, 197). This signaling mechanism may contribute to enhanced VSM contractility
in neonates with CH-induced pHTN. We cannot however eliminate the possibility that
the observed effect of TEMPOL and MitoTEMPO (both SOD mimetics which dismute O2to H2O2) to reduce vasoconstrictor reactivity could be due to the pulmonary vasodilatory
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effect of H2O2 (45, 163, 174). Additionally, TEMPOL has been shown to promote
vasodilation through direct activation of K+-channels in the membranes of vascular
smooth muscle cells (288, 289). However, the finding that MitoQ, a molecule that is not
an SOD mimetic, but instead an inhibitor of mitochondrial O2- production, similarly
abolishes CH-dependent enhancement of pulmonary arterial tone argues against this
possibility.
There are several sources of ROS that may contribute to enhanced lung levels of
ROS observed in the setting of neonatal pHTN. ROS generation by NOX, xanthine
oxidase, and uncoupled eNOS contribute to ROS production in the pulmonary circulation
of neonates with pHTN (92, 142, 254). The mitochondria are also a potent source of
cellular O2- in the pulmonary vasculature (12). In the setting of neonatal pHTN, there are
several potential mechanisms whereby lung mitoROS levels might be enhanced. In
transiently cultured PASMCs from newborn lambs, cyclic stretch stimulates
mitochondrial O2- production (278). This finding suggests that stretch on the VSM, as
might be expected in neonates with elevated pulmonary arterial pressure, stimulates
mitochondrial O2- production. Moreover, recent studies in lambs with pHTN,
demonstrate that basal mitochondrial-derived O2- levels are increased in endothelial cells
from pulmonary hypertensive lambs due to lower SOD2 (the SOD isoform present in
mitochondria that scavenges O2-) protein expression and activity relative to cells from
healthy controls (9). Mitochondrial-derived O2- limits NO bioavailability and therefore
potentiates pulmonary vasoconstrictor sensitivity (9, 10). Restoration of SOD2
expression in pulmonary arterial endothelial cells from lambs with pHTN using
adenoviral transfection not only limits mitochondrial O2- levels, but also improves NOdependent pulmonary vasodilation and increases eNOS mRNA and protein expression
to levels observed in cells from control lambs (9). These findings from the literature
suggest that increased basal mitochondrial O2- generation in neonates with pHTN
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potentiates pulmonary vasoconstriction not only by limiting NO-dependent pulmonary
vasodilation through scavenging NO, but also by reducing mechanisms for NO
production. Findings from Aim 1 of this dissertation however suggest that neonatal CH
exposure potentiates NO-dependent pulmonary dilation in animals with pHTN.
Furthermore, findings from Aim 2 indicate that mitoROS are important mediators of
augmented vasoconstriction, perhaps through a direct effect to promote enhanced VSM
contractility.
Findings from this aim suggest that mitochondrial-derived O2- contributes to
enhanced pulmonary arterial tone following neonatal CH exposure. Our studies in
isolated pulmonary arteries from both control and CH neonates used MitoTEMPO and
MitoQ, both mitochondrial-targeted strategies for reducing levels of mitochondrialderived O2-. In the presence of either compound, CH-dependent increases in pulmonary
arterial tone were eliminated suggesting a pivotal role of mitochondrial O2- following CH
exposure to augment arterial tone in the pulmonary circulation. Furthermore, the effect
of both MitoTEMPO and MitoQ to remove enhanced arterial tone in the presence of LNNA suggests that mitochondrial O2- enhance tone by promoting mechanisms of
vasoconstriction such as increased production of an endothelium-derived contractile
factor and/or by enhancing VSM contractility, not by reducing NO-dependent pulmonary
arterial vasodilation. Although we identify a potential subcellular source of O2production, we do not examine the cell-type responsible for mitochondrial O2- production.
Future studies in endothelium denuded (removed), isolated pulmonary arteries are
important to determine whether enhanced pulmonary arterial tone observed in CH
exposed neonates is a consequence of mitochondrial O2- production in the endothelium
or in VSM of the medial layer/fibroblasts in the adventitia.
Furthermore, findings related to mitochondrial-derived O2- relied on studies in
isolated, endothelium-intact, pulmonary arteries which also presents some limitations.
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The lung is a multicellular tissue with a variety of cell types such as endothelial cells (46)
and adventitial fibroblasts (189) that may contribute to regulation of pulmonary vascular
tone in the setting of pHTN. There are also factors such as NO, AVP, ET-1, and 5-HT,
released from the lung and other endocrine organs that can alter the level of tone within
the pulmonary circulation in vivo. Additionally, our studies focus on only a segment of
one branch in the arterial tree, making it difficult to extend our findings to the entire
pulmonary circulation. However, our finding that TEMPOL eliminates CH-dependent
increases in pulmonary vascular resistance in the isolated (in situ) lung, were the entire
pulmonary circulation is present, by limiting pulmonary arterial tone bolster a role for our
findings related to mitochondrial O2- in the intact pulmonary circulation.
MitoROS generation in the endothelium may lead to increased production of an
endothelium-derived contractile factor such as ET-1 (144). Enhanced mitochondrial O2levels in endothelial cells from lambs with pHTN limit eNOS mRNA and protein
expression and limit vasodilation to endogenous NO (9). NO can limit ET-1 production
and secretion by pulmonary arterial endothelial cells through downregulating expression
of preproET-1 mRNA (151). In the setting of neonatal pHTN, reduced pulmonary
vascular NO may contribute to elevations in ET-1 levels observed in neonates with
pHTN (144, 228). Findings from Aim 1 of this dissertation however, make this
interpretation unlikely in our model due to the observed effect of CH to increase NOdependent pulmonary vasodilation in neonates with pHTN. The literature also supports
a role for O2- to lead to lipid peroxidation-dependent increases in ET-1 lung levels in
neonates with pHTN (144). It is possible that in our model, mitochondrial O2- may
increase ET-1 production through other means, such as promotion of lipid peroxidation.
In addition to the possible role of mitoROS to promote activity of ET-1,
mitochondrial O2- is also important for 5-HT-induced pulmonary arterial vasoconstriction
as well. In intrapulmonary arteries from adult rats, mitochondrial O2- is important for 593

HT-induced vasoconstriction (34, 103). In isolated PASMCs from these animals, 5-HT
treatment leads to mitochondrial O2- production that is sensitive to 5-HT receptor
antagonists (103). 5-HT binds 5-HT2A receptors on rat PASMCs and stimulates influx of
extracellular Ca2+ which then leads increased mitochondrial Ca2+ uptake, mitochondrial
depolarization, and subsequent mitochondrial O2- generation from complex I (103).
Moreover, mitoROS (9, 83), 5-HT-induced pulmonary vasoconstriction (40, 49, 72), VSM
[Ca2+]i (124), and vascular tone (180, 250, 251) are known to be increased in the setting
of neonatal pHTN, suggesting that 5-HT-induced mitochondrial O2- may be an important
mediator of neonatal pHTN.
Mitochondrial O2- may increase VSM contractility in pulmonary arteries of
neonates with CH-induced pHTN by altering Ca2+ signaling and/or by increasing
myofilament Ca2+ sensitivity. In addition to their energy-generating capacity,
mitochondria also participate in regulation of [Ca2+]i (176). Studies of transiently cultured
PASMCs from adult mice have demonstrated that mitoROS contribute to acute-hypoxia
dependent increases in [Ca2+]i and subsequent VSM contraction (272). It is also
possible that in addition to a potential role to alter [Ca2+]i signaling, mitoROS may
contribute to enhanced myofilament Ca2+-sensitization. As mentioned earlier, cellular
ROS contribute to RhoA/ROK-dependent Ca2+ sensitization in adult rodents with CHinduced pHTN (145). ROK has been shown to activate actin polymerization (18). Actin
polymerization is thought to promote myofilament Ca2+ sensitization by enhancing
transmission force to the extracellular matrix (258, 293) and by increasing the assembly
of contractile units between actin and myosin (38). In cultured mouse and human
fibroblasts, treatment with rotenone, an electron transport chain complex 1 inhibitor,
reduces mitoROS production and limits cellular attachment and membrane spreading
(292), processes driven by actin polymerization (291). These findings suggest that
mitoROS promote actin polymerization, a mechanism that increases myofilament Ca2+
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sensitization.
Several intracellular signaling pathways can promote mitoROS generation. In
primary cultures of mouse microvascular endothelial cells, extracellular O2- generated by
NOX can stimulate increased [Ca2+]i which in turn results in mitochondrial O2- production
(94). In disease models such as cardiac ischemic preconditioning and angiotensin IIinduced systemic hypertension, mitoROS production in cardiac myocytes (175) and
bovine aortic endothelial cells (76) is a downstream event in several signaling pathways
such those impacted by Akt, MAP kinases, PKA, and PKC (76, 175). In disease states
such as diabetes, ischemia-reperfusion injury, multiple sclerosis, obesity, and
osteoporosis the β isoform of PKC contributes to mitoROS production and cellular
oxidant stress that may facilitate disease pathogenesis (16, 182, 244, 270). The effect
of mitochondrial O2- to mediate enhanced pulmonary arterial vasoconstriction may be a
downstream consequence of kinase signaling, perhaps PKCβ considering its role to
mediate cellular dysfunction in several disease states.
In conclusion, this aim demonstrates that augmented pulmonary arterial tone and
pulmonary vasoconstrictor sensitivity rely on mitochondrial O2- signaling. Considering
the link between PKCβ, mitoROS, and cellular dysfunction, studies in Aim 3 were
designed to pursue the contribution of PKCβ to enhanced pulmonary vasoconstriction
occurring in neonates with CH-induced pHTN.

Specific Aim 3: Define the contribution of PKCβ-signaling to enhanced vascular
reactivity following CH exposure in neonates.

Findings from Aim 2 of this dissertation demonstrate that mitochondrial O2contributes to enhanced pulmonary arterial vasoconstriction in neonates with CHinduced pHTN. The upstream signaling mechanism for mitochondrial O2- generation
95

however was still unknown. Considering previous evidence linking PKCβ signaling with
mitoROS production in several disease states, the present aim examined the hypothesis
that PKCβ-dependent mitoROS generation in pulmonary vascular smooth muscle
contributes to enhanced pulmonary arterial tone following neonatal CH. The major
findings from this aim are that 1) PKCβ signaling leads to increases in mitoROS
production in transiently cultured PASMCs from control neonates; 2) PKCβ signaling
contributes to enhanced pulmonary arterial tone and vasoconstrictor sensitivity following
CH; and 3) PKC βI and PKC βII are both expressed in pulmonary arteries from both
control and CH neonates, but they were not significantly altered by CH. Taken together,
these data demonstrate that PKCβ signaling leads to mitoROS generation in PASMCs
from neonatal rats and that PKCβ and mitoROS are important mediators of enhanced
pulmonary arterial vasoconstriction occurring in the setting of neonatal pHTN.
PKC is an important regulatory kinase in the pulmonary vasculature where it
contributes to VSM contractility and proliferation (28, 41). In the setting of neonatal
pHTN, PKC signaling is an important mediator of enhanced basal pulmonary vascular
tone (31). Additionally, studies in isolated pulmonary arteries from adult rats with
intermittent hypoxia-induced pHTN demonstrate that enhanced vasoconstrictor
sensitivity of ET-1 is sensitive to myrPKC (a myristoylated PKCα/β psudosubstrate
inhibitor) and LY-333,531 (a selective PKCβ inhibitor), but not rottlerin (a PKCδ inhibitor)
(242). These results demonstrate that enhanced pulmonary arterial vasoconstrictor
reactivity occurring in the setting of pHTN rely on PKC isoform signaling, likely PKCβ.
PKCβ is a classical PKC isoform which is regulated by both changes in [Ca2+]i
and diacylglycerol (268). Findings from aim 3 of this dissertation demonstrate that both
splice variants of PKCβ, PKC βI and PKC βII, are expressed pulmonary arteries of both
control and CH neonates. As protein expression of PKCβ splice variants was unaltered
by CH, mechanisms other than changes in protein content account for the PKCβ96

dependency of tone development and agonist-induced pulmonary vasoconstriction
observed only in neonates exposed to CH. Subcellular localization of PKC isoforms is
an important regulator of their activity (193) with increased cell membrane association
correlated with enhanced activity of PKC isoforms (193, 211, 265). In adult rats with
intermittent hypoxia-induced pHTN, PKCβ protein expression was unaltered by
intermittent hypoxia exposure, but the basal cell membrane association of PKCβ is
increased as is ET-1-dependent translocation away from the plasma membrane in
pulmonary arteries from animals exposed to intermittent hypoxia compared to normoxic
controls (242). This finding suggests that although neonatal CH does not increase
protein expression of PKCβ, it may alter the subcellular localization of PKCβ to be more
membrane associated and therefore more active.
Considering the role of Ca2+ in promoting activation of classical PKC isoforms
such as PKCβ, it is also possible that following CH exposure in neonatal rats, increased
PASMC [Ca2+]i activates PKCβ-dependent pulmonary arterial vasoconstriction. In
PASMCs collected from both control and CH-exposed piglets, basal Ca2+ is elevated in
cells from piglets exposed to CH (124). Additionally, exposure of PASMCs from either
control or CH piglets to 3 days of hypoxia in vitro increased [Ca2+]i (124). Finally,
stimulation of cultured PASMCs with U-46619 was associated with greater changes in
[Ca2+]i in cells from CH exposed piglets (124). In transiently cultured PASMCs from both
healthy control lambs and those with pHTN, Ca2+ release from intracellular stores as well
as SOCE was enhanced in cells from neonates with pHTN (223). However, this group
did not report whether there was a difference in basal Ca2+ between PASMCs collected
from control lambs and those with pHTN (223). Findings in pulmonary VSM from
neonatal piglets and lambs suggest that intracellular Ca2+ levels may be elevated in
neonates with pHTN which may then contribute to PKCβ activation.
In addition to [Ca2+]i contributing to PKCβ activation in pulmonary VSM of
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neonatal rats exposed to CH, PKCβ is also regulated by cellular redox state. Oxidative
stress associated with certain diseases such as multiple sclerosis, obesity, and
osteoporosis is thought to activate PKCβ signaling (16, 182, 252, 295). The enzymatic
structure of PKCβ contains an auto-inhibitory zone with cysteine thiols vulnerable to
reversible oxidation to form a sulfenylated (-SOH) side group (106). Protein
sulfenylation of the auto-inhibitory zone it thought to produce an increase in the catalytic
activity as well as potentiate agonist-dependent activation of PKCβ (107, 155).
An important downstream consequence of PKCβ activation and signaling is
mitoROS generation (16, 252). In this aim, we observe that PKCβ signaling promotes
mitoROS generation in isolated PASMCs from neonatal rats. PKCβ-induced mitoROS
generation occurring in disorders such as aging, multiple sclerosis, obesity, and
osteoporosis involves PKCβ-dependent translocation of the redox enzyme p66shc to the
mitochondria (16, 182, 252, 295). Normally the factor p66shc resides in the cytoplasm,
but under conditions of oxidative stress, such as that observed in neonatal pHTN, PKCβdependent phosphorylation of p66shc stimulates its translocation to the mitochondrial
inner membrane. Once there, p66shc oxidizes cytochrome c and then reduces
molecular oxygen into O2- (207, 252).
An additional potential mechanism whereby PKCβ may promote the generation of
mitoROS involves the mitoKATP channel. The mitoKATP channel is expressed on the
mitochondria and appears to be distinct from KATP channels located in the plasma
membrane in terms of its regulation and composition (135). In cardiomyocytes collected
from adult rabbits, mitoKATP channel opening was associated with increased mitoROS
generation (199). Opening of the mitoKATP channel permits K+ influx into the
mitochondrial matrix and matrix alkalization as incoming K+ ions replace H+ pumped out
by the respiratory chain (59, 85). Matrix alkalization uncouples the electron transport
chain and leads to mitoROS production (59, 85). The opening of mitoKATP channels is
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promoted by PKC signaling. In isolated mitochondria collected from homogenates of
adult rat hearts, inhibition of PKC prevented PMA-induced mitoKATP channel opening.
Although this group went further and demonstrated that PKCε contributed to mitoKATP
opening in isolated cardiac mitochondria (58), they did not test a role for PKCβ. Findings
from this aim evaluating PMA-dependent increases in mitochondrial O2- production
assessed using mitoSOX fluorescence in transient cultures of neonatal PASMCs,
demonstrate that PKCβ signals to induce mitoROS generation. There may be a
difference in which PKC isoform modifies mitoKATP channel kinetics depending on a
given cell type with VSM and cardiac muscle regulated in different ways.
We observe in this aim that PKCβ is upstream of mitochondrial O2- production
and findings from Aim 2 of this dissertation indicate that mitochondrial O2- are important
mediators of elevated pulmonary arterial tone following neonatal CH exposure.
Therefore, it is possible that PKCβ-dependent mitochondrial O2- contributes to enhanced
pulmonary arterial tone in neonates with CH-induced pHTN. Of interest, whereas
inhibition of mitochondrial O2- signaling fully alleviated elevated tone in pulmonary
arteries from CH neonates, PKCβ inhibition was only partially effective. This finding is
also true in results from the isolated (in situ) lung preparation where TEMPOL eliminated
CH-dependent enhancement of both basal tone and agonist-induced vasoconstrictor
sensitivity, whereas PKCβ inhibition only partially relieved those responses. These
findings together suggest that perhaps PKCβ is not fully inhibited by the concentration of
LY-333,531 used in these studies or that there are other mechanisms for mitochondrial
O2- production. Additionally, it is possible that there may be sources of ROS in the whole
lung that are not mitochondrial. In the discussion section for Aim 2, it was suggested
that mechanisms such as increased [Ca2+]i (103) and/or elevated cytoplasmic or
extracellular levels of O2- (94) may stimulate mitoROS generation, independent of PKCβ
signaling.
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PKCβ may also facilitate enhanced pulmonary vasoconstriction independent of
downstream mitoROS signaling. Classical PKC signaling leads to the inhibition of
myosin light-chain phosphatase via phosphorylation by the peptide CPI-17. CPI-17dependent phosphorylation of the myosin light chain leads to greater Ca2+-sensitization
and subsequent increases in vasoconstrictor sensitivity (154). Considering that PKCβ
contributes to enhanced pulmonary arterial tone and pulmonary vasoconstrictor
sensitivity in neonatal rats with CH-induced pHTN, CPI-17-dependent increases in
myofilament Ca2+-sensitivity may be involved in this response.
However, in adult rats with pHTN induced by exposure to intermittent hypoxia,
PKCβ contributed to enhanced ET-1 vasoconstrictor sensitivity and Ca2+-sensitization
without altering levels of phosphorylated myosin light-chain (242). Additionally,
activation of PKC in uterine arteries of pregnant sheep increased arterial tone without
altering levels of phosphorylated myosin light-chain (286). These findings suggest PKC
signaling, even involving PKCβ, may use pathways independent of CPI-17 to promote
Ca2+ sensitization and enhanced pulmonary vasoconstriction. As mentioned above,
actin polymerization may also contribute to enhanced vasoconstrictor reactivity
independent of changes in [Ca2+]i. CH exposure of pregnant sheep increased PKCdependent uterine artery constriction in a manner dependent on actin polymerization
(285). This finding suggested that PKC-induced actin polymerization is important for
uterine artery constriction following CH exposure during pregnancy. We observe that
antenatal CH exposure of neonatal rats increases pulmonary arterial tone and
vasoconstrictor sensitivity in a PKCβ-dependent manner, perhaps dependent on actin
polymerization.
Actin polymerization can also be promoted by mitochondrial-derived O2- (291,
292). Findings from Aims 2 and 3, demonstrate that PKCβ signaling in transiently
cultured PASMCs from neonatal rats increases mitochondrial O2- generation and that
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PKCβ and mitoROS contribute to enhanced pulmonary arterial tone following CH
exposure. It is possible that PKCβ-dependent mitoROS generation in PASMCs of
neonatal rats contributes to mitoROS-dependent actin polymerization and subsequent
promotion of myofilament Ca2+ sensitivity.
In conclusion, this aim demonstrates that augmented pulmonary arterial tone and
pulmonary vasoconstrictor sensitivity rely on PKCβ and that PKCβ signaling in neonatal
PASMCs is upstream of mitochondrial O2- generation in PASMCs from control neonates.
We know from aim 2 that mitoROS are important mediators of enhanced pulmonary
arterial tone following neonatal CH exposure. Future investigation into the link between
PKCβ and mitoROS occurring in pulmonary VSM of neonates with CH-induced pHTN is
important to understand how this pathway is activated and contributes to enhanced
pulmonary arterial vasoconstriction.
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Conclusions
The aim of this dissertation was to examine mechanisms of enhanced pulmonary
vasoconstriction occurring in CH-induced neonatal pHTN. We first investigated the
contribution of diminished endothelium-dependent pulmonary vasodilation to enhanced
pulmonary vasoconstriction. In contrast to our hypothesis, we found that following CH,
vasodilatory responses to endogenous NO were enhanced in a manner dependent on
increased eNOS protein expression and Ser1177 phosphorylation. We additionally
observed that CH did not alter VSM sensitivity to exogenous NO. We concluded that
neonatal CH exposure promotes endogenous NO-dependent pulmonary vasodilation by
upregulation of protein expression and Ser1177 phosphorylation of eNOS. Despite this
potentially adaptive response, neonates exposed to CH still demonstrated increased
baseline PVR, enhanced pulmonary vasoconstrictor sensitivity, and pHTN.
We next evaluated the role of enhanced VSM contraction involving
PKCβ/mitoROS signaling to mediate enhanced pulmonary arterial vasoconstriction. We
found that PKCβ activation in neonatal pulmonary VSM leads to mitoROS generation.
We additionally observed that PKCβ contributes to enhanced basal pulmonary arterial
tone and vasoconstrictor reactivity following neonatal CH exposure. ROS signaling
similarly contributes to enhanced pulmonary arterial basal tone and agonist-induced
vasoconstriction in CH-exposed neonates with mitoROS contributing to enhanced
arterial tone development in isolated pulmonary arteries from CH neonates. In
conclusion, these data suggest that CH augments pulmonary arterial vasoconstriction in
a manner dependent on PKCβ/mitoROS and that this response occurs despite a CHdependent increase in NO-dependent pulmonary vasodilation.
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Clinical Significance
Neonatal pHTN is a significant source of morbidity and mortality in infants (5,
246). Research into underlying mechanisms contributing to neonatal pHTN have
identified vasoconstriction as an important mediator of the disease (180, 246).
Investigation into factors that contribute to enhanced pulmonary vasoconstriction has
focused on the role of diminished pulmonary vasodilation to limit vasoconstriction (43,
83, 87). Studying mechanisms of reduced pulmonary vasodilation has yielded clinical
interventions for infants with pHTN focused on improving mechanisms of pulmonary
vasodilation (5, 246). Evaluation of the effectiveness of current vasodilator therapies
demonstrates that these strategies are met with limited success and do not improve
mortality or length/cost of hospital stay (160, 273). Therefore, investigation into
mechanisms that contribute to enhanced pulmonary vasoconstriction through promotion
of enhanced VSM tone and pulmonary vasoconstrictor sensitivity are important to help
generate new therapeutics for neonates with pHTN. Through these studies, we have
demonstrated that enhanced pulmonary arterial vasoconstriction occurring in neonates
with pHTN depends on PKCβ, a PKC isoform not previously linked to vasoconstriction in
the neonatal pulmonary circulation, and mitoROS signaling. Further, we demonstrated
that PKCβ can signal to promote mitoROS generation in neonatal PASMCs. The ability
to understand these cellular pathways involving PKCβ and mitoROS may provide a new
means of treating neonatal pHTN. Considering the need for improved understanding of
mechanisms responsible for enhanced pulmonary VSM contractility and the subsequent
contribution of those factors to enhanced pulmonary vasoconstriction, the findings from
this investigation represent a novel step toward improved therapeutic intervention for
infants with pHTN.
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Future Directions
Although our present findings support a role of PKCβ/mitoROS signaling to
mediate enhanced pulmonary arterial vasoconstriction in neonates with CH-induced
pHTN, several questions remain unanswered by the current study. Future studies are
necessary to establish the link between CH and PKCβ activation, PKCβ and mitoROS
generation, and finally the mechanism by which PKCβ/mitoROS may enhance
pulmonary arterial vasoconstriction. In addition, it is important to determine whether the
PKCβ/mitoROS signaling axis contributes to the progression and maintenance of CHinduced pHTN in neonates.
As indicated above, future studies will evaluate the upstream initiator of this
pathway following exposure to CH. Considering that ROS are important in the
development of neonatal PH (40, 142), our data suggesting that PKCβ stimulates
mitoROS production, and the known role of oxidation to activate PKCβ (106, 155, 206),
we suspect that CH stimulates PKCβ activity through oxidation of the enzyme in a feedforward fashion. However, investigation into the impact of neonatal CH exposure on
[Ca2+]i in VSM is also important considering that PKCβ is also sensitive to changes in
[Ca2+]i (268).
More investigation is important to better understand how PKCβ promotes
mitoROS generation in PASMCs from neonatal rats. The literature suggests that
signaling involving PKCβ-dependent activation of p66shc and/or mitoKATP channel
opening may contribute to mitoROS generation (16, 58, 252). Additionally, more work is
needed to better understand if neonatal CH exposure leads to PKCβ-dependent
mitoROS generation and, if so, how CH may activate this signaling pathway. CH does
not appear to impact protein expression of PKCβ splice variants, but some PKC isoforms
translocate from the cell membrane to mitochondria to stimulate mitochondrial O2production (54, 175). It is possible that subcellular localization of PKCβ may account for
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CH-dependent activation of PKCβ/mitoROS signaling.
We are also interested in the downstream mechanism of PKCβ/mitoROSdependent vasoconstriction. Dynamic actin cytoskeletal reorganization in VSM is vital to
tension generation (258, 259) and early studies from our laboratory in adult rats suggest
PKCβ/mitoROS signaling contribute to enhanced vasoconstriction in a manner
dependent on myofilament Ca2+ sensitization reliant on actin polymerization. Classical
signaling of PKC to promote Ca2+-sensitization in arterial smooth muscle relies on CPI17-dependent inhibition of myosin light-chain phosphatase (245). Evaluation of the
contribution of CPI-17-induced Ca2+ sensitization and the contribution of PKCβ in this
response is important to better understand potential mechanisms by which PKCβ leads
to enhanced pulmonary arterial vasoconstriction.
Investigation into the potential mechanism by which PKCβ/mitoROS leads to
enhanced pulmonary arterial vasoconstriction also needs to address which cell type is
responsible for observed responses. Our current findings in transiently cultured
PASMCs suggest that PKCβ/mitoROS signaling is observed in pulmonary VSM.
However, studies in endothelium-disrupted, isolated pulmonary arteries are important to
determine whether enhanced pulmonary arterial tone observed in CH exposed neonates
is a consequence of PKCβ/mitoROS acting as endothelium-derived contractile factors.
Finally, increased PKCβ and mitoROS signaling may represent early onset
responses that initiate the development of pHTN in response to neonatal CH.
Furthermore, this mechanism may contribute to the maintenance of pHTN through
vasoconstrictor actions. Future studies are necessary to evaluate the contribution of
both PKCβ and mitoROS to the development of CH-induced neonatal pHTN, and the
regression of established pHTN in this model.
In closing, the results from this dissertation as well as potential follow up
investigation could identify therapeutic targets for neonatal pHTN. The potential of this
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goal is enhanced by the recent use of the PKCβ inhibitor, LY-333-351 (13, 239) and the
mitochondrial selective ROS scavenger, MitoQ (241, 257) in clinical trials to treat
disease in adult humans.
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APPENDIX A – ABBREVIATIONS AND ACRONYMS
ACh = acetylcholine
ANOVA = analysis of variance
AVP = arginine vasopressin
BKCa = Big conductance potassium channel
BSA = bovine serum albumin
[Ca2+]i = intracellular calcium concentration
Ca2+ = calcium
CH = chronic hypoxia
DHE = dihydroethidium
eNOS = endothelial nitric oxide synthase
EGTA = ethylene glycol-bis(β-aminoethyl ether)-N,N,N’N’-tetraacetic acid
ET-1 = endothelin-1
FBS = fetal bovine serum
HBSS = Hank’s buffered saline solution
5-HT = serotonin
20-hydroxyeicosatetraenoic acid = 20 HETE
i.d. = inner diameter
i.p. = intraperitoneal
iNOS = inducible nitric oxide synthase
L-NNA = Nω-nitro-L-arginine
LV+S = left ventricle plus the interventricular septum
mitoROS = mitochondrial-derived reactive oxygen species
mitoTEMPO = 2-(2,2,6,6-tetramethylpiperidin-1-oxyl-4-ylamino)-2oxoethyl)triphenylphosphonium chloride
mRNA = messenger ribonucleic acid
N2 = nitrogen
NADPH = nicotinamide adenine dinucleotide phosphate
nNOS = neuronal nitric oxide synthase
NO = nitric oxide
NOS = nitric oxide synthase
NOX = nicotinamide adenine dinucleotide phosphate oxidase
O2 = oxygen
O2- = superoxide anion
P14 = post-natal day 14
Pa = pulmonary arterial pressure
PAF = platelet activating factor
PASMC = pulmonary arterial smooth muscle cell
Pc = microvascular capillary pressure in the lung
PE-20 = polyethylene tubing 20
PE-90 = polyethylene tubing 90
PE-160 = polyethylene tubing 160
pHTN = pulmonary hypertension
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PKC = protein kinase C
PMA = phorbol 12-myristate 13-acetate
Pv = pulmonary venous pressure
PVR = pulmonary vascular resistance
Q = perfusion rate
RNA = ribonucleic acid
ROK = Rho kinase
ROS = reactive oxygen species
RT-PCR = real-time polymerase chain reaction
RV = right ventricle
RVH = right ventricular hypertrophy
RVSP = right ventricular systolic pressure
SEM = standard error of the mean
shRNA = short hairpin ribonucleic acid
SOCE = store operated calcium entry
SOD = super oxide dismutase
SR = sarcoplasmic reticulum
SSRI = selective serotonin reuptake inhibitor
TBS = tris-buffered saline
TEMPOL = 1-oxyl-2,2,6,6-tetramethyl-4-hydroxypiperdine
Tiron = dihydroxy-1,3-benzenedisulfonic acid disodium salt
TTBS = tween-20 plus tris-buffered saline
VEGF = vascular endothelial growth factor
VSM = vascular smooth muscle
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